Identification of serine 867 as new phosphorylation site on the GABA(B) receptor : characterization of physiological effects by Abdel Aziz, Said
  
 
 
 
 
 
 
 
 
phosphorylation site on the GABAB receptor: 
 
Inauguraldissertation  
 
zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der 
von  
 
 
Said Abdel Aziz 
 
aus Basel-Stadt 
 
 
 
 
 
 
 
Zürich, 2011 
Original document stored on the publication server of the University of Basel  
edoc.unibas.ch  
 
 
This work is licenced under the agreement „Attribution Non-Commercial No Derivatives – 
2.5 Switzerland“. The complete text may be viewed here:  
creativecommons.org/licenses/by-nc-nd/2.5/ch/deed.en 
  
Genehmigt von der Philosophisch-Naturwissenschalichen Fakultät auf Antrag 
von 
 
 
Prof. Dr. Bernhard Beler 
 
 
 
Prof. Dr. Markus A. Rüegg 
 
 
 
 
Basel, 8. Dezember 2009    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prof. Dr. Eberhard Parlow  
       Dekan 
 
  
 
 
 
 
 
 
 
Dedicated to my parents 
 
 
 
 
 
 
 
 
 
 
  
Table of contents 
I. Aim of the thesis ......................................................................................................................1 
II. List of abbreviations ................................................................................................................2 
III. Introduction .............................................................................................................................4 
3.1   γ-aminobutyric acid (GABA) – Main inhibitory neurotransmitter in the vertebrate     
        CNS and its receptors .................................................................................................................4 
 
3.2  GABAB receptors - Molecular structure and physiology ..........................................................5 
 
3.2.1 Molecular Structure of GABAB receptors......................................................................6 
3.2.1.1 Heteromerization of GABAB receptor subunits GABAB1 and GABAB2 ..................6 
3.2.1.2 Molecular structure of GABAB receptor subunits GABAB1 and GABAB2 ..............7 
3.2.1.3 GABAB1 and GABAB2 subunits distribution in the brain ........................................7 
3.2.2 GABAB receptors effector mechanisms ........................................................................9 
3.2.2.1 Blocking of Ca2+channels ........................................................................................9 
3.2.2.2 Opening of K+ channels ...........................................................................................9 
3.2.2.3 Down regulation of adenylate cyclase activity .................................................. 10 
3.2.3 GABAB receptor, diseases and drugs ......................................................................... 11 
3.2.3.1 Addiction ............................................................................................................... 11 
3.2.3.2 Epilepsy ................................................................................................................. 11 
3.2.3.3 Nociception........................................................................................................... 12 
3.2.3.4 Depression and anxiety ....................................................................................... 12 
3.2.3.5 Baclofen (LioresalTM) ............................................................................................ 13 
3.2.3.6 γ-hydroxybutyric acid (XyremTM) ........................................................................ 13 
 
3.3   Phosphorylation regulates GABAB receptor function .......................................................... 15 
 
3.3.1 Central kinases in the mammalian brain ................................................................... 16 
3.3.1.1 CaMKII ................................................................................................................... 16 
3.3.1.2 PKA ........................................................................................................................ 17 
3.3.1.3 PKC ........................................................................................................................ 18 
3.3.1.4 AMPK..................................................................................................................... 19 
 
3.4   GABAB phosphorylation sites: Identification and physiological relevance ......................... 22 
 
3.4.1 PKA site: serine 892 on the GABAB2 subunit ............................................................. 22 
3.4.2 AMPK sites: serine 783 on the GABAB2 subunit and serine 917 on the GABAB 
subunit .................................................................................................................... 25 
IV. Results ................................................................................................................................... 27 
4.1  NMDA receptor activation decreases surface GABAB receptors by CaMKII- mediated    
       phosphorylation of GABAB1 at serine 867 (Manuscript) ...................................................... 27 
 
i
  
4.1.1 Abstract ........................................................................................................................ 27 
4.1.2 Introducon ................................................................................................................. 28 
4.1.3 Experimental Procedures ........................................................................................... 29 
4.1.3.1 Neuronal cultures and transfecon .................................................................... 29 
4.1.3.2 Treatment protocols for neuronal culture ......................................................... 29 
4.1.3.3 Immunocytochemistry and quanficaon  ......................................................... 30 
4.1.3.4 Co-Immunoprecipitaon ..................................................................................... 31 
4.1.3.5 GST-fusion proteins.............................................................................................. 31 
4.1.3.6 Pull-Down assay ................................................................................................... 32 
4.1.3.7 In vitro kinase assay ............................................................................................. 32 
4.1.3.8 Reverse phase-high pressure liquid chromatography (RP-HPLC) ..................... 32 
4.1.3.9 Electro spray ionizaon mass spectrometry (ESI-MS/MS) ................................ 33 
 
4.1.4 Results .......................................................................................................................... 33 
4.1.4.1 Glutamate-induced decrease of cell surface GABAB receptors is NMDA 
receptor dependent ........................................................................................... 33 
4.1.4.2 NMDA receptor-induced decrease of cell surface GABAB receptors is mediated 
through CaMKII .................................................................................................. 34 
4.1.4.3 CaMKII binds and phosphorylates GABAB receptors ......................................... 34 
4.1.4.4 Idenficaon of a CaMKII phosphorylaon site within the carboxyl -terminal of 
GABAB1 ............................................................................................................. 35 
4.1.4.5 Endogenous CaMKII phosphorylates serine 867 ............................................... 35 
 
4.1.5 Discussion .................................................................................................................... 36 
 
4.2 Supplemental results ................................................................................................................ 46 
 
4.2.1 Analysis of the GABAB1 subunit carboxyl-terminus for phosphorylaon targets ... 46 
4.2.2 Glutathione S-tranferase fusion system .................................................................... 48 
4.2.3 In vitro phosphorylaon using purified or endogenous kinases  ............................. 49 
4.2.4 High pressure liquid chromatography (HPLC) and Mass spectrometry (MS)  ......... 51 
4.2.5 The phosphospecific pS867 anbody ........................................................................ 54 
4.2.5.1 Generaon of the pS867 anbody ..................................................................... 54 
4.2.5.2 Characterizaon of the pS867 anbody  ............................................................. 54 
4.2.5.3 In vivo phosphorylaon of the GABA B1 isoform ................................................ 55 
4.2.5.4 NMDA treatment of corcal cultures increases S867 phosphorylaon  .......... 57 
4.2.5.5 Preliminary immunohistochemical results with the pS867 anbody .............. 58 
4.2.6 The phosphorylaon of S867 is physiological relevant  ............................................ 59 
V. Final discussion ..................................................................................................................... 62 
VI. References ............................................................................................................................ 67 
VII. Appendix ................................................................................................................................... I 
A. Curriculum Vitae .........................................................................................II 
B. Acknowledgements .................................................................................. III  
 
ii
  
I. Aim of the thesis 
The GABAB receptor is the metabotropic receptor for γ-aminobutyric acid (GABA), the main inhibitory 
neurotransmitter in the mammalian central nervous system (CNS). The functional receptor is a 
heteromer consisting of a GABAB1 and GABAB2 subunit. Two isoforms from the GABAB1 subunit exist; 
the GABAB1a and the GABAB1b isoform, whose distribution pattern differs throughout the brain. GABAB 
receptors manifest their inhibitory action by influencing adenylate cyclase activity, presynaptic 
voltage sensitive Ca2+ channels and postsynaptic rectifying K+ channels. The large variety of 
neurological and psychiatric disorders e.g. addiction, epilepsy, nociception and depression caused by 
GABAB receptors dysfunctions, highlight the importance for GABAB regulatory mechanisms. One such 
regulatory mechanism is phosphorylation which is the principal way to regulate GABAB receptor 
functioning. In vivo, two phosphorylation sites on GABAB receptors were identified; serine 892 and 
serine 783 and both sites play a role in synaptic plasticity.  Phosphorylation of serine 892 prolongs 
the inhibitory impact of GABAB receptors activity on the CNS and serine 783 is ascribed for its 
neuroprotective benefits.  
 
The aim of this thesis was to study the modulatory effect of phosphorylation on GABAB receptor 
functioning. The identification of serine 867, a novel physiological relevant phosphorylation site on 
GABAB receptors, contrasts with the previous serine sites. Indeed, the serine 867 is positioned on the 
GABAB1 subunit, constrasting with the GABAB2 localisation of the serines 892 and 783.  Interestingly, 
serine 867 phosphorylation is mediated by CaMKII, an abundant and relevant kinase in the CNS. 
Consequently, it is proposed that serine 867 phosphorylation could regulate surface availability of 
GABAB receptors under neuronal activation leading to synaptic plasticity modulation.  
 
My thesis is divided in three sections; introduction, results and discussion part. The introduction will 
provide background information about the structure, distribution and physiological role of GABAB 
receptors. The influence of phosphorylation on the GABAB receptors will be clarified by the 
itemization of the significant kinases in the CNS and an explanation of GABAB receptor 
phosphorylation sites serine 892 and serine 783. The results part includes a manuscript of a potential 
publication and supplemental results. The final discussion will focus on the consequences of the 
serine 867 phosphorylation on CNS function. 
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II. List of abbreviations 
1a-/- mice  transgenic GABAB1a subunit isoform deficient mice 
1b-/- mice  transgenic GABAB1b subunit isoform deficient mice 
AMPA   α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid 
AMPK   5’AMP-dependent protein kinase 
APV   D-(-)-2-Amino-5-phosphonopentanoic acid 
Ca2+-CaM  Ca2+and Calmodulin 
CaMKII   Ca2+and Calmodulin-dependent kinase 
CID   collision-induced dissociation 
Cl-    chloride 
CNS   central nervous system 
DAG   diacylglycerol 
DAPI    4’, 6-Diamidin-2’-phenylindoldihydrochlorid 
DIV   day in vitro 
eGFP   enhanced green fluorescent protein 
EPSC   excitatory postsynaptic current 
ER   endoplasmic reticulum 
ESI-MS   electrospray-ionisation mass spectrometry 
GABA   gamma-amino butyric acid 
GABAA   gamma-amino butyric acid type A receptor 
GABAB   gamma-amino butyric acid type B receptor 
GABABC  gamma-amino butyric acid type C receptor 
GDP   guanosine diphosphate 
GHB   gamma-hydroxybutyrate 
GIRK G-protein-coupled inwardly-rectifying potassium channels 
GPCR   G-protein coupled receptor 
GST    glutathione s-transferase 
GTP   guanosine-5'-triphosphate 
HPLC    high pressure liquid chromatography 
IPSC   fast inhibitory postsynaptic current 
Da   Dalton 
KN-93 N-2-3-4-Chlorophenyl-2-propenyl-methylamino-methyl-
phenyl-N-2-hydroxyethyl-4-methoxy-benzene-sulphonamide 
LTP   long term potentiation 
MCAO    middle cerebral artery occlusion 
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mGluR   metabotropic glutamate receptor 
MS    mass spectrometry 
NMDA   N-methyl-D-aspartate 
NMDAR  NMDA-receptor 
PDE    phosphodiesterase 
PKA    cyclic AMP-dependent protein kinase 
PKC   protein kinase C 
PKI   protein kinase inhibitor 
PSD   postsynaptic density 
RP-HPLC  reverse-phase high pressure liquid chromatography 
SD   standard deviation 
SDS-PAGE  sodium dodecylsulfate polyacrylamide gel electrophoresis 
TR-FRET   time-resolved fluorescence resonance energy transfer 
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III.  Introduction 
3.1 γ-aminobutyric acid (GABA) – Main inhibitory neurotransmitter in the vertebrate CNS 
and its receptors 
 
Around 60 years ago, three groups first described GABA in the mammalian brain (Awapara, 1950, 
Roberts, 1950, Udenfriend, 1950). Four years later, Kuffler (Kuffler, 1954) and Florey (Florey, 1954) 
discovered the inhibitory activity of GABA on crayfish. Following that discovery, it took less than 10 
years for GABA to become generally accepted as the principal inhibitory transmitter, especially in 
vertebrate brain (Krnjevic, 1963, Krnjevic, 1965, Jasper, 1969, Obata, 1969, Krnjevic, 1967, Dreifuss, 
1969, Obata, 1967, Galindo, 1969, Curtis, 1970). There are two major classes of GABA receptors: on 
one hand, ligand-gated ion channels (ionotropic) GABAA/C receptors and on the other, G-protein-
coupled (metabotropic) GABAB receptors. Ionotropic GABAA/C receptors (Chebib, 1999) directly gate 
chloride channels; the inward flow of negatively charged chloride ions quickly inhibits the 
postsynaptic cells. Ionotropic GABAA and GABAC receptors (also known as GABAA-ρ receptors) can be 
discriminated by their sensitivity to pharmacological agents such as barbiturates, benzodiazepines, 
steroids and bicuculline.  Indeed, GABAA but not GABAC receptors are sensitive to such agents. 
Beginning of the 1980s, Hill and Bowery identified, also based on the distinct pharmacological profile 
for GABA and its analogues (especially bicuculline and baclofen), the second class of GABA receptors 
(Hill, 1981); the metabotropic GABAB receptors.  
 GABAB receptors function via multistep pathways involving guanine nucleotide binding 
proteins (G-proteins). Effects of GABAB receptor activation are slow, long lasting and thus considered 
as modulatory compared to GABAA/C activation. They even include the induction of long-term 
changes in synaptic strength. GABAB receptors generate late inhibitory postsynaptic potentials 
(IPSPs) which are important for the fine tuning of inhibitory neurotransmission by increasing 
membrane K+ conductance. Late IPSPs have a slower onset and a prolonged duration compared with 
fast IPSPs deriving from GABAA/C receptors. Furthermore, postsynaptic GABAB receptors modulate 
neurotransmitter release by depressing Ca2+ influx via voltage-activated Ca2+ channels, whereas 
postsynaptic GABAB receptors mainly couple to inwardly rectifying K
+ channels (Bowery, 2002). 
GABAB receptors also inhibit adenylate cyclase; possibly modulating transcription factors (Steiger, 
2004) and kinases (Diverse-Pierluissi, 1997, Couve, 2002, Ren, 2003). 
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3.2 GABAB receptors - Molecular structure and physiology 
 
In 1997, Kaupmann et al. successfully isolated cDNAs for the two GABAB1 subunit isoforms; GABAB1a 
and GABAB1b (Kaupmann, 1997). Thereupon, GABAB2, the other GABAB receptor subunit was 
discovered. The GABAB1 (either GABAB1a or GABAB1b subunit isoform) functionally heteromerizes with 
the GABAB2 subunits (Bettler, 2004, Calver, 2002, White, 1998).  This organization principle was at 
that time completely novel for G-protein coupled receptors (GPCRs). GABAB2 subunits escorts the 
GABAB1 subunit to the cell-surface and appears to be the G-proteins linking component of GABAB 
receptors. GABAB1 subunits are necessary for agonist binding (Margeta-Mitrovic, 2000, Calver, 2001, 
Galvez, 2001, Pagano, 2001). Most researchers in the field expected the existence of many GABAB 
receptor subtypes due to the various subcellular distributions and different GABAB pharmacological 
properties (e.g. different binding properties for the two GABAB receptor antagonists phaclofen and 
CGP (Bonanno, 1992, Gemignani, 1994), Cunningham, 1996, Deisz, 1997, Mohler, 1999, Yamada, 
1999, Bowery, 2002), similarly to what was shown for the metabotropic glutamate receptors. 
Additionally, GABAB receptors structure is homolog to the metabotropic glutamate receptors 
(mGluRs) structure as both receptors belong to the same GPCR family (Conn, 1997).  Nonetheless, 
there is only one common agreement which is the existence of two GABAB receptor subtypes; the 
GABAB(1a,2) heterodimers and the GABAB(1b,2) heterodimers (Bettler, 2004). The broad functional and 
pharmacological diversity of the GABAB system emerges from different parameters including the 
heteromerizing nature of the GABAB receptors, the homolog but not identical molecular structure of 
the different subunits and the localization pattern of two GABAB receptors in different brain regions. 
The following chapters analyze these parameters. The description of GABAB receptor localization 
pattern will be restricted here to the brain, although functional GABAB receptors can also be found in 
peripheral organ and tissues (Ong, 1990), e.g. esophageal sphincter (Smid, 2000), uterus, spleen and 
in rat heart myocytes (Calver, 2000).  That restriction was taken in regard to the determined extent 
of the thesis. 
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3.2.1 Molecular Structure of GABAB receptors 
 
3.2.1.1 Heteromerization of GABAB receptor subunits GABAB1 and GABAB2 
Most experiments with cloned GABAB1 and GABAB2 subunits expressed in heterologous cells and 
sympathetic neurons show that individual subunits are functionally inert (Filippov, 2000), a 
characteristic that differs  from other dimeric GPCRs, in which the different subunits are functional 
when individually expressed (Bouvier, 2001). Active GABAB receptors assemble into heteromers 
composed of GABAB1 and GABAB2 subunits (Marshall, 1999, Mohler, 1999, Bettler, 2004). As 
mentioned before, GABAB1 subunits are involved in the binding of GABA (Kaupmann, 1998a), 
whereas GABAB2 subunits are responsible for escorting GABAB1 subunits to the cell-surface and for 
activating G-proteins (Margeta-Mitrovic, 2000, Margeta-Mitrovic, 2001, Calver, 2002, Galvez, 2001, 
Robbins, 2001). Mouse genetic studies addressed the question whether cloned subunits guarantee 
classical GABAB functions in vivo. Mice missing either the GABAB1 subunits or GABAB2 subunits, from 
here on referred to as GABAB1 deficient or GABAB2 deficient, unveil a complete deficit of typical 
biochemical, electrophysiological and behavioral GABAB responses (Prosser, 2001, Schuler, 2001, 
Quéva, 2003, Gassmann, 2004). Additionally, GABAB subunit knock-out mice reveal the 
predominantly heteromeric nature of native GABAB receptors. They show a substantial down-
regulation of GABAB2 and GABAB1 protein in GABAB1 deficient and GABAB2 deficient mice respectively, 
supporting that the native interaction between GABAB1 and GABAB2 subunits prevents their 
degradation. 
On the other hand  GABAB2 deficient mice show small G-proteins dependent GABAB responses 
whereas GABAB1 deficient mice did not (Gassmann, 2004), probably due to the inhibition of 
constitutively active K+-channels, contrasting with the normally observed activation of K+-channels. It 
is unclear whether the atypical GABAB1 responses are of physiological relevance or an artifact of the 
knockout situation. The debate about the assembly of GPCRs is going towards higher order 
oligomerization structures than dimerization. Time-resolved fluorescence resonance energy transfer 
(TR-FRET) even foresights in GABAB receptors transfected HEK 293 and COS cells, a structural and 
functional multimeric model for GABAB receptor organization: “dimers of dimers” (Maurel, 2008), but 
the in vivo proof of a higher order oligomerization is still missing. Nevertheless, the possibility that 
the classical dimeric organization of the GABAB will in future extended to a higher degree of 
organization by means of different ways e.g. unknown receptor interactors, cannot be excluded at 
that time. 
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3.2.1.2 Molecular structure of GABAB receptor subunits GABAB1 and GABAB2 
GABAB subunits share a high degree of homology; by comparing the amino acid sequence of rat 
GABAB1b (Kaupmann, 1997) and GABAB2 subunit, we find at protein level, a similarity and an identity 
of 45% and 35% respectively, aligning by pileup program human GABAB2 (AF099033) and rat GABAB1b 
(Y10370) coding regions (Martin, 1999). Many structural features are shared by the two subunits, 
namely, seven-transmembrane-domains, a major characteristic for the GPCR family, an extracellular 
chain at the amino terminus and at a long carboxyl-terminal tail. GABAB1 and GABAB2 subunits 
interact via the carboxyl-terminal resident coiled-coil domains in (Pagano, 2001). Coiled-coil domains 
are dimerization motifs found in numerous proteins, such as leucine-zipper transcription factors, KATP 
channels (Zerangue, 1999) or N-methyl-D-aspartate (NMDA) receptors (Scott, 2001). Proximal to 
coiled-coil domains, the carboxyl-terminal region of the GABAB1 subunit contains an arginine-based 
endoplasmic reticulum (ER) retention signal RSRR. This domain prevents the escape of unassembled 
GABAB1 subunits from ER then solely restricting surface expression to correctly assembled 
heteromeric receptors.  Coiled-coil interaction of both carboxyl-terminals shields the retention signal 
then allowing the heteromeric receptor to exit from ER to the surface (Couve, 1998, Margeta-
Mitrovic, 2000, Pagano, 2001, Gassmann, 2005). The GABAB2 subunit carboxyl-terminal is around 100 
aminoacids longer than the one from the GABAB1 subunit (Marshall, 1999). Carboxyl-terminals of 
GABAB receptor subunits harbor several phosphorylation sites important for regulating receptor 
signaling or localization (chapter 3.2). GABAB2 amino-terminal is comparable to the one found on 
GABAB1b subunit isoform, but shorter (Martin, 1999).  Additional reasons for the diversity in the 
GABAB system are the two different isoforms of the GABAB1 subunit, GABAB1a and GABAB1b isoforms. 
Further GABAB1 cDNA isoforms than GABAB1a and GABAB1b are not found conserved among different 
species and the existence of stable protein products different from the GABAB1a, GABAB1b and GABAB2 
could not be demonstrated in vivo. The structural difference in both isoforms is based on the 
exclusive presence of a pair of sushi repeats at the amino-terminal of the GABAB1a isoform (Blein, 
2004). Sushi repeats, also known as complement control protein modules, or short consensus 
repeats, are found in other GPCR as well (Grace, 2004), mediating a wide variety of adhesion protein 
interactions (Lehtinen, 2004). Differential promoter usage from the GABAB1 gene generates GABAB1a 
and GABAB1b isoforms (Bischoff, 1999, Steiger, 2004). 
 
3.2.1.3 GABAB1 and GABAB2 subunits distribution in the brain 
The GABAB receptors are distributed throughout the whole brain; their transcripts and binding sites 
are expressed in the brain in almost all neuronal cell populations, in glial cells they are not or only 
marginal expressed (Benke, 1999, Bischoff, 1999). The pharmacological difference of the GABAB 
responses bases on the differing distribution pattern of the GABAB subunits. In various brain regions 
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including cerebellum, ventrobasal thalamus and hippocampus a diversing pre- and postsynaptic 
localization of the GABAB receptor has been described (Kulik, 2002, Kulik, 2003); e.g. in hippocampus, 
GABAB receptors are found on GABAergic and glutamatergic terminals, mainly extrasynaptical and 
rarely at presynaptic membranes. Most of the GABAB receptors are consequently located far from 
the GABA release sites presumably requiring pooling of synaptical released GABA to be activated. 
The lack of specific GABAB1 subunit antibodies or pharmacological compounds, demanded the 
generation of the GABAB1a and GABAB1b deficient mice, referred as 1a
-/- and 1b-/- mice respectively 
(Vigot, 2006). The 1a-/- and 1b-/- mice have become an essential tool for studying GABAB receptor 
localization and function. Quantitative analysis of immunogold labeled GABAB1 subunits in wild-type 
(WT) and 1a-/- or 1b-/- mice unveils a localization of the GABAB1a subunit in the CA1 region of the 
hippocampus on presynaptic terminal of the glutamatergic synapses (Vigot, 2006, Guetg, 2009), 
whereas the GABAB1b subunit was more abundant at postsynaptic density (Guetg, 2009). 
Electrophysiological experiments confirm this distribution, showing that the inhibition of excitatory 
postsynaptic currents (EPSCs) at glutamatergic synapses was reduced drastically in 1a-/- mice 
compared to WT mice (Vigot, 2006), indicating that presynaptic GABAB responses are mainly 
GABAB(1a,2) receptor subtype dependent at CA3-to-CA1 synapses. No difference of the inhibitory 
postsynaptic currents (IPSCs) inhibition was observed for 1a-/- and 1b-/- compared to WT mice. Both 
GABAB1 subunit isoforms seem to contribute equally to GABAB response on presynaptic GABAergic 
terminals. The 1b-/- mice show a 50% postsynaptic reduction in K+-currents compared to WT mice, 1b-
/- mice K+-currents were similar in WT mice, meaning that the postsynaptic GABAB response is 
predominantly mediated by GABAB1b isoform (Vigot, 2006). In layer 5 neocortical pyramidal neurons, 
inhibition of dendritic Ca2+ spikes is believed to be mediated exclusively by GABAB (1b, 2) receptor 
subtypes. Presynaptic inhibition of GABA release was mediated on the contrary through GABAB (1a, 
2) receptors (Perez-Garci, 2006). NMDA-independent LTP in lateral amygdale reveals that GABAB1a, 
but not GABAB1b is mainly localized at cortical afferents (Shaban, 2006). Similar functional segregation 
of GABAB (1a, 2) and GABAB (1b, 2) receptor subtypes was also observed in the thalamus (Ulrich, 
2007).  
14
  
3.2.2 GABAB receptors effector mechanisms 
 
The metabotropic GABAB receptor acts through G-proteins activation. GABAB receptors couple to 
Giα- and G0α-type G-proteins (Asano, 1986, Campbell, 1993, Greif, 2000, Menon-Johansson, 1993, 
Morishita, 1990). They are present on as well inhibitory as excitatory terminals where they either 
regulate the release of GABA (autoreceptors) or glutamate (heteroreceptors). Both, autoreceptors 
and heteroreceptors, act by inhibiting the presynaptic and voltage sensitive Ca2+ channels. At the 
postsynaptic side, GABAB receptors inhibitory actions are mediated through the K
+ channels. Both ion 
channels are modulated through the Gβγ G-protein subunits. GABAB receptors, finally, also inhibit 
adenylate cyclase activity, trough Giα/G0α G-protein subunits. This chapter discusses the inhibitory 
mechanisms of GABAB receptors in more detail.  
  
3.2.2.1 Blocking of Ca2+channels 
Presynaptic GABAB receptors act through voltage-dependent inhibition of high-voltage activated N 
type (Cav2.2) and P/Q type (Cav2.1) Ca2+ channels (Amico, 1995, Cardozo, 1995, Menon-Johansson, 
1993, Mintz, 1993, Newberry, 1985, Pfrieger, 1994, Poncer, 1997, Scholz, 1991, Takahashi, 1998). 
Both Ca2+ channel types are shown to trigger neurotransmitter release at presynaptic terminals (Wu, 
1997). L-type Ca2+ channels seem to get reulated by GABAB receptors; either inhibitory (Amico, 1995, 
Maguire, 1989, Marchetti, 1991) or facilitatory (Shen, 1999). However, the effect was shown to be 
indirect and protein kinase C (PKC) activity dependent. GABAB receptors also inhibit and disinhibit T-
type Ca2+ channels (Crunelli, 1991, Futatsugi, 1998, Matsushima, 1993, Scott, 1986, Scott, 1990). The 
Ca2+ channels inhibition can be modulated by the action potential frequency, where strong 
depolarization relieves Ca2+ channels from their G-protein mediated inhibition (Herlitze, 1996, Ikeda, 
1996, Zamponi, 1997).  
 
3.2.2.2 Opening of K+ channels 
Through the activation of inwardly rectifying GIRK or Kir3 K+ channels GABAB receptors induce late 
IPSCs (Luscher, 1997, Schuler, 2001). Ba2+, a Kir3 channel blocker, inhibits the GABAB-induced late 
IPSCs (Jarolimek, 1994, Pitler, 1994, Thompson, 1994). The physiological effect of the activation of 
Kir3 channels is a K+ efflux resulting in hyperpolarization. The baclofen-induced outward currents are 
absent in hippocampal neurons from Kir3.2 and GABAB1 deficient mice (Luscher, 1997, Schuler, 
2001). The rectifying properties of synaptical evoked late IPSCs differ between studies. On one hand, 
stimulus-evoked and spontaneous late IPSCs in dopaminergic neurons are inwardly rectifying and 
similar to the baclofen activated ones (Hausser, 1994). On the other hand, baclofen induces also 
linear or even outwardly rectifying conductance, suggesting the contribution of channels other than 
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Kir3, e.g. inactivating voltage gated K+ channels (Saint, 1990) and a small Ca2+ conductance contribute 
to late IPSCs.  
 
3.2.2.3 Down regulation of adenylate cyclase activity 
The GABAB receptor dependent activation of Gi/0α subunits influences the adenylate cyclase activity. 
Indeed, in brain slices it is shown that GABAB receptor agonists inhibit basal or forskolin induced 
adenylate cyclase activity (Xu, 1986, Knight, 1996). The physiological confirmation of this effect 
comes from cerebral cultures taken from microdialysed living rats’ experiments (Hashimoto, 1997). A 
microdialysis cannula was implanted into the striatum of the rats, trough which forskolin was 
administrated. The application of GABA and GABAB receptor agonist baclofen dampens the increase 
of forskolin stimulated cAMP formation whereas GABAB receptor antagonist CGP5426 abolishes the 
reduction in cAMP formation. The main relevance of adenylate cyclase regulation by GABAB 
receptors is still unclear. A regulatory role on transcription factors Steiger, 2004) and kinases, 
especially cAMP-dependent protein kinase A (PKA) or even on cAMP, Ca2+ and calmodulin dependent 
vesicle priming is conceivable (Diverse-Pierluissi, 1997, Couve, 2002, Ren, 2003). Interestingly, few 
studies claim that Gβγ subunits of the GABAB receptors activated G-protein can also weakly stimulate 
adenylate cyclase activity (Bowery, 2002, Calver, 2002). 
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3.2.3 GABAB receptor, diseases and drugs 
 
A number of clinical studies suggest that GABAB might play an important role in alleviating symptoms 
of different maladies like addiction, epilepsy, nociception and multiple sclerosis. This chapter informs 
on the current knowledge of GABAB receptors contribution in regard to addiction, epilepsy and 
nociception and on baclofen and GHB, two therapeutic relevant GABAB receptors agonists. 
 
3.2.3.1 Addiction 
The GABAB agonists reduce human and animal craving for different drugs. Preliminary clinical studies 
with cocaine abusing patients show a reduced demand for cocaine after baclofen administration 
(Brebner, 2002, Ling, 1998). Animal experiments also support baclofen therapeutic effectiveness 
against cocaine abuse. Baclofen suppresses intravenous self-administration of cocaine in rodents 
(Brebner, 2000, Campbell, 1999, Roberts, 1996, Shoaib, 1998). A reduced self-administration after 
baclofen administration was also observed for heroine (Xi, 1999). GABAB agonists are also effective in 
clinical studies against alcoholism (Addolorato, 2002), reducing alcohol intake (Colombo, 2000, 
Daoust, 1987, Smith, 1999).  GHB application shows promising effects against nicotine dependence 
(Dewey, 1998, Dewey, 1999). The GABAB receptor acts inhibitory on the dopaminergic cells, 
especially in the nucleus accumbens. The nucleus accumbens is part of the mesolimbic dopamine 
system and is believed to be involved in the reward and reinforcement circuitry. Drugs of abuse 
increase extracellular dopamine levels in the nucleus accumbens. GABAB receptor activating 
compounds could block the effect of drugs of abuse, by decrasing the dopamine release in the 
mesolimbic system, and are then interesting therapeutic candidates for the control of addiction (Xi, 
1999). 
 
3.2.3.2 Epilepsy 
The GABAB receptors participate in the generation of absence seizures within the thalamus (Kim, 
1997). The exact receptor-mediated mechanism is still unclear. Animal experiments show that GABAB 
agonists increase the probability for seizures. The application of GABAB antagonists on the other 
hand reduces the risk for seizures. The activation of postsynaptic GABAB receptors on thalamocortical 
neurons produces a prolonged neuronal hyperpolarization facilitating the Ca2+ spiking. That, in turn, 
is relayed to the cerebral cortex. One evident phenotype of the GABAB1 deficient mice is the 
appearance of absence seizures (Prosser, 2001, Schuler, 2001). Interestingly, the absence of seizures 
seen in the GABAB1 deficient mice and GAERS rats, a model for absence epilepsy (Marescaux, 1992), 
are different. Indeed, the seizures in the GABAB1 deficient mice are rare and longer in duration which 
is indicative for “atypical” absence seizures. Conversely, GAERS rats show seizures characterized by 
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frequent and short EEG bursts. It is conceivable that the different composition of GABAB receptor in 
nervous cell system is important in the inherited predisposition to epilepsy (Gambardella, 2003). 
However, GAERS rats offer no evidence for differences in the GABAB1 subunit populations or post-
receptor mechanisms. The eventual availability of subtype specific GABAB receptor antibodies would 
enable detection of GABAB receptor variants alterations. 
 
3.2.3.3 Nociception 
Clinical trials with the GABAB agonist baclofen reveal an antinociceptive property of the GABAB 
receptor activity on e.g. vagoglossopharyngeal and ophtalmic-postherpetic neuralgias, diabetic 
neuropathy, and migraine (Bowery, 1993, Fromm, 1989, Hering-Hanit, 1999, Sindrup, 2002).  Further 
animal experiments; rodent models of acute pain, such as tail-flick, hot-plate tests, or chronic pain 
models in rats, support this antinociceptive effect of baclofen (Balerio, 2002, Przesmycki, 1998, Cui, 
1998, Wiesenfeld-Hallin, 1997). The acute pain tests with GABAB receptor deficient mice confirmed 
the antinociceptive role (Schuler, 2001). The GABAB1 deficient mice display a pronounced 
hyperalgesia in the hot-plate and tail-flick tests, as well as reduced paw-withdrawal thresholds to 
mechanical pressure (Bettler, 2004). These two mice models suggest that the absence of functional 
GABAB receptors most probably results in an increased central hyperexcitability of spinal nociceptive 
pathways. Intrathecal application of baclofen, that exerts its effects in the brain and the spinal cord, 
relieves central pain in patients with spinal lesions or after cerebral strokes (Herman, 1992, Taira, 
1995).  
 
3.2.3.4 Depression and anxiety 
20 years ago Lloyd et al. (Lloyd, 1985) demonstrated an upregulation in GABAB binding sites occurring 
in rat frontal cortex after chronic administration of antidepressant drugs and as a result of 
electroconvulsive therapy. First these findings were disputed, but nowadays there is no doubt for the 
contribution of the GABAB receptor in the etiology of depression (Enna, 2004). The primary question 
is surely whether the modulation or the antagonism of GABAB receptors produces antidepressant-
like or anxiolytic effects. The GABAB1 deficient or GABAB2 deficient mice are more anxious but exhibit 
also an antidepressant-like behavior (Mombereau, 2005), suggesting that the loss or blockade of 
GABAB receptor functions produce antidepressant-like effects. Several studies performed with GABAB 
receptor antagonists in a variety of animal models support that statement (Cryan, 2005). However, 
until clinical studies are undertaken, it will not be clear whether antidepressant activity will emerge 
from an action at the GABAB receptor. Activation of the GABAB receptor in the dorsal periaqueductal 
grey of rats impairs one-way escape in the elevated T maze test, which is consistent with an 
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anxiolytic or panicolytic effect. In addition, baclofen has been reported to reduce the incidence of 
panic attacks in patients following the systemic administration. 
 
3.2.3.5 Baclofen (LioresalTM) 
Several centrally acting neuronal inhibitory drugs, including benzodiazepines, mediate their effects 
by the GABAA receptors activation. In contrast, the only compound in current clinical use, baclofen (β 
p-chlorophenyl-GABA), mediates its effects directly through the activation of GABAB receptors. 
Baclofen, a common antispastic medicament, was first prescribed in 1972 for therapeutic use (Faigle, 
1972), even before GABAB receptors discovery.  30 years later baclofen is still the only GABAB 
receptor specific agonist, although the receptors structure was described already a decade ago 
(Jones, 1998, Kaupmann, 1998a, White, 1998), acclaiming a clinical poor penetration of the blood-
brain barrier. Its beneficial effects on epilepsy, nociception, depression, anxiety and drug addiction 
have been discussed already. Muscle-relaxant properties of baclofen are well established clinically, 
making it the drug of choice in the treatment of spasticity associated with cerebral palsy, multiple 
sclerosis, stiff-man syndrome and tetanus. Still, the large doses that have to be administered in order 
to compensate for the poor blood brain barrier diffusion are rarely tolerated by the patients. Indeed, 
the adverse effects of large orally intake of baclofen include dizziness, nausea, sedation and 
hallucinations. That has been largely overcome by the intrathecal administration of baclofen using an 
indwelling pump. Since this form of administration is locally, it reduces the incidence of adverse 
effects and the risk of drug tolerance. Finally it was shown that baclofen suppresses cognitive 
behavior in animals (McNamara, 1996). Although this property, baclofen is of little consequence to 
clinical medicine, there is the chance that GABAB receptor antagonists might provide a novel 
opportunity for treating cognitive impairment. Already some animal models for learning and memory 
retention have been established (Bowery, 2002) and the first clinical trials of GABAB receptor 
antagonist have started recently (Helm, 2005).  
 
3.2.3.6 γ-hydroxybutyric acid (XyremTM) 
The γ-hydroxybutyric acid (GHB) acts mainly through the GABAB receptors (Kaupmann, 2003). GHB is 
a naturally occurring, is a short-chain fatty acid related to GABA, rapidly producing effects likened to 
a combination of alcohol (euphoria, reduced anxiety, drowsiness, loss of motor control and ecstasy 
(enhanced sensuality, emotional warmth) (Galloway, 2000). GHB is used recreationally at raves, or to 
heighten sexual pleasure. GHB has also been used as a “health product” for its soporific activity. Body 
builders make use of GHB as steroid replacement, although no anabolic effects have yet been 
convincingly reported in animals (Nicholson, 2001). The clinical evidence shows GHB abuse produces 
severe dependence and withdrawal symptoms. Two large clinical studies where GHB was prescribed 
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as part of treatment program for alcoholism and heroine abuse, showed that 10–15% of patients 
became dependent and addicted to GHB (Gallimberti, 2000).  GHB combination with alcohol leads to 
severe coma. It is unfortunately also used by criminals who are taking advantage of the anterograde 
amnesia, muscle relaxation and the fast disinhibition caused by GHB intake, to abuse their unaware 
victims. 
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3.3 Phosphorylation regulates GABAB receptor function 
 
Considering that GABAB receptors play a crucial role in synaptic inhibition it is important to 
understand the mechanisms involved in their modulation and the impacts of such modulations on 
the synaptic function. One major mechanism regulating GPCRs function is phosphorylation of their 
intracellular domains by protein kinases (Pitcher, 1998). For the most GPCRs, phosphorylation results 
in the reduction of the effector coupling and receptor removal from cell-surface (Tsao, 2000). Both 
effects lead to the phenomena called desensitization. Desensitization is described as the decrease of 
a receptor response over time despite the continuous presence of the agonist. Ferguson wrote in 
2001 (Ferguson, 2001) about GPCR desensitization: “The waning of GPCR responsiveness to agonist 
with time represents an important physiological feedback mechanism that protects against both 
acute and chronic over stimulation of GPCRs”. They are two major types of receptor desensitization: 
the homologous and the heterologous desensitization.   
The homologous desensitization results from a receptor phosphorylation by G-protein coupled 
receptor kinases (GRKs), leading to the binding of cytoplasmic inhibitory proteins known as arrestins 
(Craft, 1995).  The binding of arrestins prevents receptor-dependent activation of its associated G-
proteins and, therefore, its effectors. Furthermore, binding of arrestins to GRK phosphorylated 
receptors is believed to initiate GPCRs endocytosis, or sequestration (Ferguson, 1996), into the 
recycling endosomes (von Zastrow, 1992). In the resensitization the dephosphorylation by a 
membrane associated phosphatase returns the internalized receptors to cell-surface (Pitcher, 1995).  
On the other hand, the heterologous desensitization means phosphorylation of GPCRs by second 
messenger–dependent kinases, e.g. PKA, calcium/calmodulin-dependent kinase II (CaMKII), protein 
kinase c (PKC) or 5′-AMP activated protein kinase (AMPK). Receptor phosphorylation by these kinases 
impairs receptor-dependent stimulation of their G-proteins (Benovic, 1985, Pitcher, 1992, Hosey, 
1999). 
The following chapter focuses on the main modulatory kinases in the mammalian brain, being the 
serine/threonine kinases CaMKII, PKA, PKC and AMPK. It highlights too their central role in neuronal 
processes including LTP. In the second part of this chapter the current knowledge of the 
phosphorylation sites on GABAB receptors and their actual physiological relevance, especially in 
regard to their regulatory effect on desensitization mechanisms, are explained. Only, the 
phosphorylation site serine 883 on the GABAB2 subunits, revealed by phosphoproteomic analysis of 
cortical human synaptosomes (DeGiorgis, 2005), will not be included in this discussion due to the 
absence of its physiological relevance. 
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3.3.1 Central kinases in the mammalian brain 
 
3.3.1.1 CaMKII 
The calcium/calmodulin-dependent kinase II (CaMKII) is very abundant in the CNS (Erondu, 1985) and 
is implicated in a wide variety of neurobiological processes (Braun, 1995, Lisman, 2002, Hook, 2001). 
CaMKII is encoded by four genes in mammals: α, β, γ, and δ; each of the genes encodes a protein 
having an amino-terminal kinase domain, followed by a regulatory region with an autoinhibitory 
sequence and a calmodulin binding site. The carboxyl-terminal is usually called association domain 
and is responsible for the subunit assembly into large (from 8 to 14 subunits) multimers. Structural 
differences between CaMKII isozymes are primarily the consequence of differences within their 
variable regions, localized between the regulatory region and association domain (Hudmon, 2002). 
All four genes also undergo alternative splicing in these variable regions.  In CNS α and β CaMKII 
isozymes are predominant (Miller, 1985). The γ and δ isozymes are found at low levels in all tissues 
but are enriched in non-neuronal tissues (Tobimatsu, 1989).  For instance, the δ CaMKII is found in 
the heart whereas α, β and δ in skeletal muscles.  The CaMKII is activated by the Ca2+-CaM binding to 
its regulatory domain, resulting in the relief of the catalytic domain, from its inhibition by 
autoregulatory sequences proximal to CaM binding site. That allows CaMKII to phosphorylate itself 
on the autophosphorylatory site threonine 286 and to phsophorylate the CaMKII substrates. As 
aforementioned, the CaMKII plays a central role in neuronal processes which is outlined by its 
abundant localization in the nervous cell system. The CaMKII is found in dendritic spines and listed as 
a major constituent of the postsynaptic density, PSD (Kennedy, 1983). The CaMKII is strongly 
involved in the regulation of synaptic plasticity. The PSD is a tiny, amorphous structure located 
beneath the postsynaptic membrane of the synapses in the CNS, visible under the electron 
microscope as tight complexes of post-synaptic junctional proteins. 
The glutamatergic excitatory synaptic transmission in the brain is mediated trough NMDA and AMPA 
glutamate receptor activation. Activity-dependent changes in AMPA receptor signaling represent a 
key mechanism for the brain plasticity and are the basis of learning and memory formation. The LTP 
in hippocampal pyramidal cells is the best established model for plasticity. Although the molecular 
mechanisms for LTP are not entirely defined; it is well accepted that the Ca2+ influx through NMDA 
receptors initiates the changes seen during LTP (Malenka, 1999, Lisman, 2003, Malenka, 2004, 
Collingridge, 2004). The intracellular increases in Ca2+ level activate CaMKII that in turn 
phosphorylates the AMPA receptors, leading to their recruitment to the spines PSD (Xie, 2007). The 
α-CaMKII deleted mice show impaired CA1 LTP and spatial learning (Silva, 1992a, Silva, 1992b). The 
same phenotype is observed in mice with a point mutation preventing autophosphorylation at 
threonine 286 (Giese, 1998). The CaMKII even modulates the morphology of dendritic spines through 
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binding and bundling of F actin (Okamoto, 2007) or through the phosphorylation and activation of 
guanine-nucleotide exchange factor Rac-1 GEF kalirin-7 (Xie, 2007). That makes of CaMKII a kinase of 
primer interest in the CNS research.  
 
3.3.1.2 PKA 
The adenosine-3’, 5’-cyclic monophosphate (cAMP) was the first second messenger to be identified. 
During the past 30 years, a large number of studies have elucidated the fundamental role of cAMP in 
cellular responses to hormones and neurotransmitters. The cAMP activates protein kinase A (PKA). 
The PKA consists of a complex of two regulatory ©- and two catalytic ©- subunits. R-subunits are 
encoded by four genes Riα, Riβ, RIIα and RIIβ, whereas C-subunits are encoded by three; Cα, Cβ and 
Cγ. The cAMP binding to PKA R-subunits induces their dissociation from the C-subunits. The PKA 
activity is important for the induction of long-term synaptic, physiological and behavioral changes 
and can be seen as another key player in the learning and long-term memory consolidation (de 
Toledo-Morrell, 1984, Ardenghi, 1997, Barad, 1998, Bach, 1999, Barros, 2000).  The PKA has also a 
crucial role in the higher CNS functions; regulatory mechanisms are present in order to control the 
PKAs activity. For example, the PKA activity downregulation is achieved through endogenous protein 
kinase inhibitors (PKIs). The PKIs are shown to disrupt LTP formation in hippocampus and/or to 
impair the long-term memory consolidation. Interestingly, with Rp-cAMPS, the inactive enantiomer 
of cAMP, the same effects are observed (Barad, 1998, Spencer, 2002, Hyman, 2001). Application of 
the Sp-cAMPS, PKA activators, induces the LTP and enhances memory consolidation (Bach, 1999, 
Ardenghi, 1997).  
The perfusion of a constitutively active isoform of the PKA catalytic subunit into the CA1 pyramidal 
neurons is sufficient to induce persistent, long-lasting synaptic facilitation (Duffy, 2003). Consistently, 
evidence from the literature proves that PKA activation enhances the long-term memory function 
dependent on the hippocampus, the brain region which is known, from studies of amnesic patients 
and experimental animals, to be of eminent importance for long-term memory formation. The PKA 
activation has been shown to reverse long-term memory deficits and the extended PKA activity, by 
systemic administration of phosphodiesterase (PDE)  nhibitors, preventing the cAMP breakdown, 
improving the hippocampal function in aged rats (de Toledo-Morrell, 1984). The application of 
rolipram, a selective PDE4 inhibitor, or  PKA activators (e.g. dopamine receptor agonists) in aged mice 
with memory deficits improved their long-term memory consolidation and facilitated LTP (Bach, 
1999, Barad, 1998). The enhancing effects of PKA on memory consolidation also appear to extend to 
interconnected cortical regions, such as entorhinal and posterior parietal cortex (Ardenghi, 1997). 
PKA activation enhanced retrieval in these cortical regions, whereas inhibition of PKA blocked 
memory retrieval. That was seen in rats, where PKA activators have been infused bilaterally into the 
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CA1 of rats (Barros, 2000, Barros, 2001).Thus, the activation of PKA in several interconnected cortical 
and hippocampal circuits enhance consolidation and possibly the retrieval of memory. Hence, it is 
not surprising that PKA is considered as an interesting compound for developing effective 
therapeutics for cognitive disorders such as age related cognitive decline, post-traumatic stress 
disorder and drug abuse (Arnsten, 2005). 
 
3.3.1.3 PKC 
The protein kinase C (PKC) influences the neurite outgrowth or several neuronal functions, for 
instance; alcohol actions, ischemic preconditioning and pain The PKC family is separated in three 
subgroups; the conventional PKC (cPKC), the novel PKC (nPKC) and the atypical PKC (aPKC). The PKC 
consists of, again, an R- and a C-domain tethered together by a hinge region. The C-region is highly 
conserved among the different isoforms and to a lesser degree, among the C-region of other 
serine/threonine kinases. The second messenger requirement for the activation of PKC differs 
according to the isoforms as a result of differences between the R-regions of a same class. The cPKC 
isoforms PKCα, PKCβ and PKCγ are diacylglycerol (DAG) and Ca2+ responsive, through the archetypal 
C2 domains. The nPKC isoforms PKCδ, PKCε and PKCη are DAG sensitive but Ca2+ insensitive, as their 
do not retain Ca2+ at their C2 domains. Finally, the aPKC isoforms PKCζ and PKCι/λ have altered C2 
domains and are DAG and Ca2+ insensitive. Their regulation is mediated through their amino-terminal 
PB1 domains. The PKCε is expressed at higher levels in the brain, compared to the other tissues 
(Shirai, 2008), suggesting its meaningful role in the nervous system. In the PKCε null mice, a higher 
sensitivity to the behavioral effects of ethanol is observed conjointly to a reduced rate of ethanol 
self-administration. Conditional expression of PKCε in basal forebrain, amygdale and cerebellum of 
these mice rescues hypersensitivity and restores the ethanol intake. The hypersensitivity and 
avoidance of ethanol in PKCε KO mice appears to be mediated by GABAA activation, since the 
allosteric GABAA activators such as pentobarbital and diazepam increase the PKCε KO mice 
locomotor activity compared to WT mice (Hodge, 1999, (Choi, 2002).  
As mentioned, CaMKII is an essential player for LTP formation. The PKCε, conversely, although 
necessary is not sufficient to induce the LTP. In the hippocampus two different types of LTP exist; the 
LTP in Schaffer collaterals-CA1 pathway, and the one in the Mossy fibers to CA3 pathway. The first 
one is Ca2+-dependent and involves postsynaptic NMDA receptor phosphorylation by PKCγ (Saito, 
2002) whereas the second takes place in the presynaptic neurons, where PKCε is enriched consistent 
with its role in LTP at this synapse (Koide, 1992, Saito, 1993). Indeed, the presence of PKCε at nerve 
terminals is involved in phorbol ester-induced enhancement of glutamate exocytosis and in 
phorbolester-induced synaptic potentiation (Saitoh, 2001, Dumuis, 1988). The by transcardial 
perfusion applied phorbolester translocated PKCε toward the synaptic side of the nerve terminal. It is 
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thought that PKCε activated by phorbol ester might interact with the microfilament F-actin and 
change its conformation, thereby increasing transmitter release. Therefore it is expected that PKCε 
contributes to Mossy fiber LTP by increasing the presynaptic neurotransmitter release. However the 
mechanism by which PKCε is activated presynaptically during LTP is not fully understood. One 
potential mechanism involves the contribution of arachidonic acid as a retrograde messenger 
produced by the postsynaptic neuron following NMDA receptor activation.  Indeed, the diffusion of 
arachidonic acid to the Mossy fiber terminal would then allow presynaptic PKCε activation and would 
cause a persistent potentiation of evoked responses (Dumuis, 1988, Kasahara, 1995). The PKCε has 
been reported to be also involved in nocioceptor sensitization (Premkumar, 2000, Tominaga, 2001). 
Indeed, PKCε directly phosphorylates TRPV1, a capsaicin receptor. TRPV1 is involved in the sensation 
of thermal and inflammatory pain (Davis, 2000). Through the PKCε phosphorylation the 
desensitization or potentiation of TRPV1 is possible (Mandadi, 2006, Dai, 2004), appointing PKCε as 
potential therapeutic target for pain regulation.  
Additionally, the PKCε and its specific activators and inhibitors seem to be involved in neuronal 
preconditioning and were investigated in hippocampal slices (Raval, 2003, Lange-Asschenfeldt, 2004) 
and primary cultured neurons (Wang, 2004, Di-Capua, 2003). The phenomenon “preconditioning” 
refers to sub-leathal and mild ischemic insults promoting tolerance against more severe subsequent 
ischemic insults in organs such as the heart and the brain. According to these studies, NMDA and 
adenosine receptor-mediated preconditioning requires the PKCε activity. Altough the mechanism of 
PKCε mediated neuronal preconditioning is not fully understood, these findings suggest that PKCε 
may have a protective role in apoplexy. Recently, Shimomura et al. demonstrated a decrease of PKCε 
levels at the core of focal cerebral ischemia, and interestingly this decrease was prevented by 
hypothermia, a well known neuroprotective mechanism (Shimomura T, 2007). How hypotheramia 
exactly alters PKCε levels is currently unknown. In the electron microscopy the PKCε localization at 
presynaptic terminals is revealed at nerve fibers (Saito, 1993 Tanaka, 1994). There, it was also shown 
that nerve growth factor induced neurite outgrowth is improved by PKCε overexpression and 
accordingly, downregulation of PKCε expression inhibits that effect (Hundle, 1995). The PKCε induced 
neurite outgrowth is blocked by RhoA, a member of the Ras homolog gene family, indicating an 
involvement of RhoA in the PKCε induced neurite outgrowth (Ling, 2004). 
 
3.3.1.4 AMPK 
The nervous cell system requires a big part of total body energy, and neurons are particularly 
vulnerable to energy deficits as their metabolism is rather inflexible and their nutrient storage 
capacity is poor. The adenosine monophosphate (AMP)-activated protein kinase AMPK was known 
for the last 35 years as a simple homologue of a yeast non-fermenting gene.  Only recently AMPK has 
25
  
been recognized as a central player in the maintenance of balanced cellular and body energy levels. 
The AMPK is unsurprisingly highly expressed in the CNS (Turnley, 1999, Culmsee, 2001). During the 
high metabolic activity or pathological states of anoxia and ischemia the decrease in cellular ATP 
levels rapidly activates AMPK coinciding with AMP increase. The AMPK then increases ATP 
generation by increasing cellular glucose uptake and the biogenesis of glucose transporter 4 (Winder, 
2001).  
The AMPK has a heterotrimeric structure consisting of a catalytic α subunit (α1 and α2) and two non-
catalytic regulatory subunits; β subunit (β1, β2. And β3) and γ subunit (γ1, γ2 and γ3) (Hardie, 2007). 
All the three subunits are required for the formation of a stable and fully functional AMPK complex. 
Each subunit possesses unique structural components facilitating the characterization of their 
specific roles in regulating activity and AMPK functioning in mammalian cells. The catalytic subunits 
have a highly conserved amino-terminal domain including the activating phosphorylation site 
threonine 172 and an autoinhibitory site. 
The AMPK β subunit is a scaffold/docking subunit that contains an amino-terminal myristoylation site 
responsible for targeting the AMPK to membranes. Additionally the β subunit is an internal glycogen-
binding domain and a carboxyl-terminal α- and γ-subunit binding domain, essential for the formation 
of stable AMPK heterotrimers (Woods, 1996, Iseli, 2005, Towler, 2007, Turnley, 1999). The β subunits 
contain several regulatory phosphorylation sites implicated in nuclear localization of AMPK as well as 
regulation of AMPK catalytic activity. The γ subunits possess variable amino-terminal region, 
followed by highly conserved cystathionine-b-synthase sequence motifs, forming the two functional 
Bateman domains. The Bateman domain 1 and Bateman domain 2 are the structures responsible for 
binding adenine nucleotides, such as AMP or ATP. The decrease of the ATP/AMP ratio, caused by 
enhanced metabolic activity, anoxia, or ischemia, activates the AMPK. AMP binds to the Bateman 
domains, induces a conformational change in the heterotrimeric AMPK structure, increasing the 
AMPK’s activity.  
Under physiological conditions the AMPK signaling, especially in hypothalamus, plays an important 
role in the mammalian feeding behavior (Kim, 2004). The majority of identified AMPK substrates are 
either enzymes or transcription factors controlling carbohydrate and lipid metabolism (Kahn, 2005). 
Pathophysiological regulation of AMPK signaling, e.g. ischemia or anoxia, leads to excitotoxcity, 
oxidative and metabolic stresses. The application of AMPK activators protects hippocampal neurons 
or astrocytes from the excitoxicity (Culmsee, 2001, Blasquez, 2001). Oxygen and glucose deprived 
hippocampal slice cultures show an increase of the activated AMPK (McCullough, 2005). Focal stroke 
models where mice are subjected to middle cerebral artery occlusion (MCAO), confirm that increase 
in vivo (Murphy, 2003). However, there is some discrepancies in literature, as it is reported that 
MCAO subjected mice show decrease of the behavioral deficits after stroke (McCullough, 2005), or 
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even provide sustained neuroprotection for days after the stroke (Li, 2007) following the AMPK 
inhibitor treatments. The differences in cell-type and conditions might contribute to the divergent 
findings. The AMPK remains an interesting target for the development of medication for stroke 
injuries or diseases involving the energy deregulation. 
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3.4 GABAB phosphorylation sites: Identification and physiological relevance 
 
3.4.1 PKA site: serine 892 on the GABAB2 subunit 
 
The phosphorylation of GPCRs generally results in a reduction in the receptor activity, an increase in 
the desensitization or the removal of the receptor from the cell-surface (Tsao, 2000). In 2002, Couve 
et al. described a controversial effect of the GABAB receptor phosphorylation by the PKA in neurons. 
They showed that PKA phosphorylation of the GABAB2 subunits at serine 892 (S892) leads to a 
reduction of GABAB receptors desensitization. Also, they provided the preliminary evidence of a 
potential participation of GABAB receptors in the well documented phenomenon of β-adrenergic-
dependent facilitation of GABAergic transmission in cerebral cortex and cerebral Purkinje cells 
(Sessler, 1995, Saitow, 2000).   
Using whole-cell patch clamp recording in primary cultures of rat hippocampal neurons, they showed 
that application of baclofen induces K+ channel activation. Short repeated applications of baclofen 
result in a clear reduction of the amplitude of the GABAB evoked K
+ currents. It is also known that the 
GABAB mediated K
+ response desensitizes and that intracellular perfusion of cAMP significantly 
reduces the agonist and time-dependent desensitization. Consistently, the PKA inhibitors largely 
prevent this effect of cAMP perfusion. Following the cAMP perfusion, baclofen induces K+ currents 
desensitization, indistinguishably from control neurons and this already from the beginning of the 
perfusion. That implies a cAMP-dependent regulation of GABAB receptor mediated K
+ responses 
trough the activation of PKA. The purified PKA phosphorylates glutathione-S-transferase (GST) fusion 
proteins containing the complete carboxyl-terminal domain of the GABAB2 subunit, termed GST-CR2. 
Moreover, the detergent-solubilized brain extracts also phosphorylates GST-CR2 proteins suggesting 
that endogenous brain PKA is active in brain extracts. The increase of cAMP concentration on brain 
extracts augments phosphorylation and Walsh peptide application, a PKA inhibitor, diminishes the 
phosphorylation signal. The carboxyl-terminal domain of the GABAB2 subunit contains a strong 
consensus site for PKA at S892 (Kennelly, 1991). The GST-CR2 fusion proteins with an alanine 
mutation at S892, the GST-CR2 S892A, no longer get phsophorylated by endogenous brain PKA. The 
PKA phosphorylation of the complete GABAB receptor is observed in COS cells, transfected with 
GABAB1 and GABAB2 complementary DNA (cDNA). After metabolic labeling with [
32P] orthophosphate, 
immunoprecipitation of a phosphorylated GABAB2 subunit from COS cells lysate was found. However, 
no significant phosphorylation of GABAB1 subunit was observed. Interestingly, forskolin treated COS 
cells show an increase in GABAB2 subunit phosphorylation, indicating a PKA activity. Consistently, 
transfection of alanine substituted GABAB2 subunits S892A cDNA in COS cells show only a weak basal 
phosphorylation of the immunoprecipitated GABAB2 subunits. The [
35S] methionine labeling and 
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immunofluorescence analysis of WT and S892A exclude differences in protein expression, stability or 
membrane targeting, other expressing systems like the HEK 293 or the CHO cells confirmed that 
result.  The comparison of the tryptic maps from the GABAB2 WT and GABAB2 S892A show the loss of 
major, by the [32P] orthophosphate labeled SDS-PAGE gel and trypsin digested phosphorylation 
peptides in the map of GABAB2 S892A, accrediting PKA phosphorylation of the recombinant whole 
GABAB2 subunit at S892. To investigate the possible functional effect of S892 phosphorylation by PKA 
on K+ currents, HEK 293 cells stably expressing Kir3.1 and Kir3.2 K+ channel subunits and transiently 
expressing GABAB1 and GABAB2 subunits, were analyzed by whole-cell recordings after the 
administration of GABA. In agreement with the results from hippocampal neurons, short-pulses of 
GABA application result in K+ current desensitization.  The same results were obtained with the 
GABAB2 WT and the GABAB2 S892A expressing neurons. The application of cAMP reduces the 
desensitization for the WT form, but not for the S892A form, confirming that the S892 
phosphorylation is responsible for the GABAB receptor amelioration of the desensitization after PKA 
activation. There are many possible ways how S892 modulates K+ response desensitization. The 
concentration-response curves for GABAB2 and GABAB2 S892A show no differences in the potency of 
GABA on GABAB receptors in presence or absence of cAMP. To study possible effects of cAMP on K
+ 
channels, K+ currents were analyzed in HEK 293 cells expressing Kir3.1 and Kir3.2 K+ channels along 
with GABAB1 and either the GABAB2 WT or the GABAB2 S892A. The chord conductance for GABA 
induced current is increased in the presence of cAMP for hyperpolarized holding potentials of WT 
GABAB receptors consistent with the assumed role of PKA phosphorylation on the GABAB receptor 
desensitization reduction. However, the S892A GABAB receptors show overlaying current-voltage 
relationships in the presence or absence of cAMP, in accordance with the lack of cAMP effect on 
desensitization of mutant receptors.  From all the current-voltage relationships, it can be observed 
that the reversal potential for the GABA-activated K+ currents is unchanged by cAMP, indicating that 
properties of inwardly rectifying K+ channels are unaffected by PKA activation.  
The K+ response desensitization might also be regulated by a decreased coupling of GABAB receptors 
to Gαi/o subunits. The [
35S] GTPγS binding assay within the CHO cells stably transfected with GABAB1 
and GABAB2 offers a good mean to solve this question However, there were no differences in the 
GABA induced EC50 or the maximal [
35S] GTPγS binding between membranes derived from cells 
exposed to control medium or to a forskolin containing medium. Attenuation of the K+ 
desensitization response by the PKA caused by different amounts of functional cell-surface GABAB1 or 
GABAB2 heterodimers was excluded using the whole-cell enzyme-linked immunesorbent assay of HEK 
293 cells transiently transfected with the GABAB1 and the GABAB2 subunits before and after PKA 
activation. The controls are untransfected cells or cells expressing MYC-tagged GABAB1 alone that are 
sequestered within the ER show no cell-surface binding of the MYC antibody. The signal was 
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observed in MYC-tagged GABAB1 transfected cells after membrane permeabilization. A robust cell-
surface expression of GABAB1 was detected after coexpression of GABAB2 and the GABAB1 amount 
expressed on cell-surface. The cell-surface stability of receptor heterodimers was verified in cells 
incubated with the MYC antibody. Loss of the cell-surface antibody was analyzed after the incubation 
at 37°C. During the short-term treatment baclofen showed no significant effect on receptor 
internalization. The PKA activation, despite the significantly reduced detriment of cell-surface 
heterodimers containing GABAB2, had only little effect on the GABAB2 S892A containing dimers. 
Altogether, these results imply that phosphorylation of the GABAB2 S892 by PKA strengthens GABAB 
receptors at the cell-surface, enhancing the effector coupling of GABAB receptors. In immunoblots of 
crude brain membranes anti-pS892, recognized at the S892 phosphorylated GABAB2 subunits. That 
detection could be blocked by adding of the chemically phosphorylated synthetic peptides (the ones 
used for immunization); confirming specificity of the anti-pS892 antibody and showing S892 
phosphorylation in the mammalian CNS. The colocalization studies demonstrate that GABAB2 S892 
phosphorylated GABAB receptors are enriched in the periphery of the cell body and abundant within 
the edges of neuronal projections. This indicates that a significant pool of phosphorylated GABAB2 
subunits is located in vicinity of the cell-surface. In cultured hippocampal cells it was studied with 
anti-pS892 antibody whether the native GABAB2 S892 phosphorylation is in consequence of the 
active PKA in the CNS. The phosphorylation was studied in the presence or the absence of 8-Br-
SpcAMP, a stable (and membrane permeable) activator of the PKA. The 8-Br-SpcAMP leads to a 
significant increase in the GABAB2 S892 phosphorylation, but there are no changes in total amount of 
the GABAB receptors. To investigate the role of GABAB receptor activation on GABAB2 S892 
phosphorylation, cultured cortical neurons were exposed to baclofen or CGP62349, a GABAB receptor 
antagonist, blocking the effect of baclofen. Baclofen decreases basal phosphorylation of the S892, 
CGP62349 inhibits that reduction. The baclofen treatment had no effect on total amounts of GABAB 
subunits. The activation of Gαi through GABAB receptors results in a reduction of cAMP 
concentrations, diminishing the PKA activity and the S892 phosphorylation. The physiological 
implications of S892 phosphorylation were recessed using a signaling cAMP level increasing pathway, 
which was done through β-adrenergic receptor activation. The noradrenaline application to the 
cultured cortical cells, cotransfected with the GABAB2 and β2 adrenergic receptors, shows an increase 
of the S892 phosphorylation. The phosphorylation of S892 was monitored after the incubation of 
forskolin or isoproterenol (a β-adrenergic agonist) plus 8-Br-Rp-cAMP. The forskolin stimulates as 
expected S892 phosphorylation in the cultured neurons, the S892 phosphorylation was also 
stimulated on the isoproterenol treatment. The 8-Br-Rp-cAMP pretreatment reduced the 
enhancement of the S892 phosphorylation by the β-adrenergic stimulation; the control protein 
amounts are unchanged. They also indicate that the signaling pathways modulating cAMP 
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concentration and modify the PKA activation have significant affects on GABAB receptors S892 
phosphorylation in cortical and hippocampal neurons. In conclusion, GABAB2 S892 phosphorylation 
underlies enhanced coupling of GABAB receptors to inwardly rectifying K
+ channels after PKA 
activation in hippocampal neurons. 
 
3.4.2 AMPK sites: serine 783 on the GABAB2 subunit and serine 917 on the GABAB1 
subunit 
 
Most of the identified AMPK substrates are involved in the control of carbohydrate and lipid 
metabolism. Kuramoto et al. showed the first neuroprotective target of AMPK activity, namely, the 
GABAB receptors (Kuramoto, 2007).  A yeast two-hybrid screen of a rat brain library using the GABAB1 
cytoplasmic tail identified the AMPK α1 subunit as interacting protein. The coprecipitation analysis of 
endogenous proteins in rat brain extracts confirmed the result. The α1 and α 2 AMPK isoforms and 
the GABAB1 and the GABAB2 subunits were found to be associated together. The fluorescence 
microscopy in neuronal processes of cultured hippocampal neurons reveals that colocalization, 
especially in neuronal processes or in the nucleus. The GST-fusion proteins of carboxyl-terminal tails 
of both GABAB receptor subunits; GST-CR1 and GST-CR2, were phosphorylated by the endogenous 
AMPK in rat brain extracts and by purified AMPK. The two major phosphorylation sites were 
identified combining high pressure liquid chromatography and masspectrometry; the serine 917 
(S917) on GABAB1 subunits and the serine 783 (S783) on GABAB2 subunits.  
In the HEK 293 cells transiently expressing GABAB1, GABAB2 subunits and the K
+ channels Kir 3.1 and 
3.2, a time-dependent rundown of K+ currents was observed. The rundown was caused by a GABA 
internal perfusion via a patch pipette, containing ATP and GTP. The application of AMP reduced the 
rundown. The transfection of the GABAB2 subunits serine 783 alanine substitution mutants (S783A) 
inhibits even that rundown. The activation of the cultured hippocampal neurons, where metformin 
activated the AMPK, still shows in the GABAB1 S917A mutants the rundown after baclofen 
administration. It suggests the S783 phosphorylation has a stabilizing effect on the K+ channels 
activation by GABAB receptors. The phosphospecific antibody, anti-pS783, recognizes the AMPK 
phosphorylated GABAB2 subunits, but not the S738A mutant. Phenformin, an AMPK activating drug, 
increases in transfected HEK 293 as well cultured hippocampal cells the phosphorylation of the S783. 
The immunofluorescence experiences using anti-pS783 antibody reveal a minority of cellular GABAB2 
subunits is phosphorylated at S783. To assess whether the AMPK is necessary for S783 
phosphorylation, an inactive AMPK mutant was transfected into cultured hippocampal neurons. The 
S783 phosphorylation signal was significantly decreased in the hippocampal regions CA3 and dentate 
gyrus (DG), only on the injured side of the brain; the anti-pS783 immunoreactivity was enhanced. The 
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total GABAB2 amount was unaltered in response to ischemia. To address the question whether the 
S783 phosphorylation exerts a neuroprotective effect cultured hippocampal neurons underlying the 
catabolism inhibition (using deoxyglucose plus azide) and the glycolysis, causing the AMPK to activate 
and the GABAB2 S783 to get phosphorylated, were studied. The expression of the WT or the S783A 
mutant of GABAB2 subunits in these cells causes significant decreases in survival after the anoxic 
insults in cells expressing the mutant. Kuramoto et al. support with these results previous findings of 
the neuroprotective effect of AMPK during metabolic insults (Culmsee, 2001). But they did not 
address whether the coupling of the GABAB receptors to the Ca
2+ channels was also affected. If 
phosphorylation works by promoting coupling between the receptor and G-proteins, like it seems to 
be the case, AMPK activation would not only accentuate hyperpolarization in response to 
postsynaptic action of GABA, it would promote also its presynaptic effects inhibiting glutamate 
release. 
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IV. Results 
The results chapter is divided in two parts. First, the actual manuscript for a potential publication 
concerning the identified phosphorylation site serine 867 (S867), located on the GABAB1 subunits. 
Second, supplemental results are added to explain and actualize the previous findings.  This includes 
the results from the preliminary sequence analysis showing the first phosphorylation experiments 
and indicating the phosphorylation of S867.  That part also contains the latest results showing the 
predominant GABAB1b subunit isoforms S867 phosphorylation in vivo. Additionally, a potential NMDA 
receptor dependent mechanism regulating S867 phosphorylation is presented. Finally the 
electrophysiological findings proving the regulatory effect of S867 phosphorylation on the GABAB 
receptor function. Some chapters of the second part will flow into the next manuscript.  
 
4.1 NMDA receptor activation decreases surface GABAB receptors by CaMKII-mediated 
phosphorylation of GABAB1 at serine 867 (Manuscript) 
 
4.1.1 Abstract 
 
GABAB receptors are G-protein-coupled receptors for gamma-aminobutyric acid (GABA), the main 
inhibitory neurotransmitter in the brain. Depending on their subcellular localization GABAB receptors 
exert distinct regulatory effects on synaptic transmission. While presynaptic GABAB receptors inhibit 
the release of neurotransmitters, postsynaptic GABAB receptors inhibit neuronal excitability by gating 
Kir3-type K+ channels. In hippocampal pyramidal neurons postsynaptic GABAB receptors are 
abundant around excitatory synapses and their cell surface availability was reported to be controlled 
by glutamate. However, the mechanism by which glutamate regulates surface GABAB receptor levels 
has not been studied. Here, we report that in primary hippocampal neurons activation of N-methyl-
D-aspartic acid (NMDA) receptors decreases GABAB cell surface levels by promoting their 
internalization. This internalization is dependent on Ca2+ influx and can be blocked by inhibiting 
CaMKII. We show that serine 867 in the carboxyl-terminus of the GABAB1 subunit (GABAB1S867) is 
phosphorylated by CaMKII. Preventing phosphorylation of the GABAB1 carboxyl-terminus by mutation 
of GABAB1S867 to alanine renders GABAB receptors refractory to NMDA-mediated internalization. 
These results indicate that NMDA receptor activation controls the availability of surface GABAB 
receptors through CaMKII-mediated phosphorylation of GABAB1S867. The regulation of GABAB 
receptor surface levels may provide a mechanism that increases the time-window of postsynaptic 
neuronal excitability upon NMDA receptor activation. 
 
33
  
4.1.2 Introduction 
 
The modulation of synaptic transmission and strength depends on mechanisms regulating the 
number of neurotransmitter receptors at the plasma membrane and consequently their availability 
to neurotransmitters. Surface trafficking of the ionotropic neurotransmitter receptor in response to 
synaptic activity has been extensively studied (Moss, 2001, Inoue, 2003). In contrast, little is known 
about the mechanisms that regulate the trafficking of GABAB receptors in response to synaptic 
activity. GABAB receptors are the metabotropic receptors for γ-aminobutyric acid (GABA), the main 
inhibitory neurotransmitter in the brain. They exist as obligate heteromers composed of GABAB1 and 
GABAB2 subunits. Both subunits are required for normal receptor functioning (Kaupmann, 1998a, 
Prosser, 2001, Schuler, 2001, Gassmann, 2004). The GABAB1 subunit binds GABA, whereas the 
GABAB2 subunit is responsible for escorting GABAB1 to the cell surface and for G-protein coupling 
(Bettler, 2004). Depending on their subcellular localization GABAB receptors exert distinct regulatory 
effects on synaptic transmission (Couve, 2000, Bowery, 2002, Ulrich, 2007). Presynaptic GABAB 
receptors inhibit the release of GABA (autoreceptors) and other neurotransmitters (heteroreceptors) 
(Scanziani, 1992, Jarolimek, 1997, Yamada, 1999). Postsynaptic GABAB receptors inhibit neuronal 
excitability by activating Kir3-type K+ channels that shunt excitatory currents and induce membrane 
hyperpolarization (Luscher, 1997). Two different GABAB1 subunit isoforms exist, GABAB1a and 
GABAB1b, giving rise to the receptor subtypes GABAB(1a,2) and GABAB(1b,2). These receptor subtypes are 
differentially distributed in neurons (Kaupmann, 1997, Bischoff, 1999). In hippocampal pyramidal 
neurons GABAB1a is most abundant presynaptically, whereas GABAB1b is predominant postsynaptically 
(Vigot, 2006, Guetg, 2009). 
Basal endocytosis of GABAB receptors can be observed in heterologous cells (Grampp, 2007, Wilkins, 
2008) as well as in neurons (Fairfax, 2004, Grampp, 2008), where it is confined to the 
somatodendritic compartment (Vargas, 2008). Upon basal endocytosis GABAB receptors are 
delivered via dynamin- and clathrin-dependent pathways to lysosomes for degradation (Grampp, 
2007, Vargas, 2008). 
Contradicting results were found regarding the regulation of surface GABAB receptor levels upon 
exposure to agonist. While some reported agonist accelerated endocytosis (Ramoino, 2006, Laffray, 
2007, Grampp, 2008), others did not see GABAB receptor internalization upon GABA application 
(Couve, 2002, Fairfax, 2004, Grampp, 2007, Vargas, 2008). Interestingly, a recent study demonstrated 
that exposure of cortical neurons to glutamate, but not GABA, decreases surface GABAB receptors by 
promoting their degradation via proteosomes (Vargas, 2008). Due to the prominent localization of 
postsynaptic GABAB receptors in spines opposite glutamatergic boutons (Kulik, 2003, Lopez-Bendito, 
2004, Kulik, 2006) the modulation of surface GABAB receptor levels by glutamate could be of 
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functional relevance. However, the glutamate receptors involved as well as the signaling mechanisms 
downstream of receptor activation have not been identified. Glutamate release from presynaptic 
neurons activates ionotropic as well as metabotropic glutamate receptors. Ionotropic glutamate 
receptors are divided into AMPA, NMDA and kainate receptors based on pharmacological and 
structural criteria (Collingridge, 1989). AMPA receptors primarily function as Na+ channels, with rapid 
activation and deactivation kinetics. They serve as mediators of fast excitatory neurotransmission. 
NMDA receptors additionally flux Ca2+ ions and have slower kinetics than AMPA receptors. A unique 
property of NMDA receptors is their voltage dependent activation, a result of ion channel  
block by extracellular Mg2+ ions. Under certain conditions, the Ca2+-influx through NMDA 
receptors promotes the activation of Ca2+/Calmodulin-dependent protein kinase II (CaMKII) 
(Malenka, 1989a, Malinow, 1989, Lisman, 2002). 
In the current study, we focused on unraveling the mechanism by which glutamate regulates surface 
GABAB receptor levels in primary hippocampal neurons, using a pharmacological approach. We 
report that NMDA receptor activation decreases surface GABAB receptor levels and provide evidence 
that this is at least in part due to increased internalization. Moreover, we show that this mechanism 
is CaMKII dependent and involves direct phosphorylation of serine 867 in the carboxyl-terminus of 
GABAB1. The regulation of GABAB surface levels by NMDA receptor activation may provide a 
mechanism to regulate neuronal excitability and synaptic strength. 
 
4.1.3 Experimental Procedures 
 
4.1.3.1 Neuronal cultures and transfection  
 High-density primary hippocampal neuronal cultures were prepared from 18.5-day old rat embryos 
and cultured in Neurobasalmedium supplemented with B27 (Invitrogen) at a density of ~750 
cells/mm2 on poly-L-lysine coated coverslips as described previously (Brewer, 1993, Goslin, 1998). At 
day in vitro (DIV) 7, neurons were co-transfected with GABAB1b (HA-GB1b-eGFP or HA-GB1bS867A-
eGFP) and GABAB2 (Myc-GB2) expression vectors using Lipofectamin 2000 (Invitrogen). The HA- and 
Myc-tags were located at the very N-terminus of the extracellular domain of GABAB1b and GABAB2, 
respectively. Gene expression was under control of the neuron specific synapsin-1 promoter (gift 
from T. Oertner/K. Svoboda). 
 
4.1.3.2 Treatment protocols for neuronal culture 
All treatments were performed in conditioned medium at 37°C / 5% CO2. Control neurons were 
incubated for 30 min with 5 μM glycine (Sigma-Aldrich). Glutamate treatment: neurons were 
incubated for 30 min with 50 μM glutamate (Sigma-Aldrich) and 5μM glycine. NMDA treatment: 
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neurons were incubated for 3 min with 75 μM N-Methyl-D-aspartic acid (NMDA, Sigma-Aldrich) and 5 
μM glycine, and returned to conditioned medium for 27 min (adapted from (Kim, 2007). APV, KN-93 
and EGTA treatment were applied prior to glutamate or NMDA treatment. Treatment procedures 
were as follows: APV treatment: neurons were preincubated for 2 h in 100 μM D-(-)-2-Amino-5-
phosphonopentanoic acid (APV, Tocris); KN-93 treatment: neurons were preincubated in 10 μM. N-
[2-[[[3-(4-Chlorophenyl)-2-propenyl]methylamino]methyl]phenyl]-N-(2-hydroxyethyl)-4-
methoxybenzenesulphonamide (KN-93, Tocris) for 2 h; EGTA treatment: neurons were preincubated 
in 2 mM Ethylene glycol-bis-(2-aminoethyl)-N,N,N', N'-tetraacetic acid (EGTA, Sigma-Aldrich) for 10 
min (adapted from (Faure, 2007)). 
 
4.1.3.3 Immunocytochemistry and quantification 
 Neurons were fixed with 4% paraformaldehyde (PFA, Sigma-Aldrich) in phosphate buffered saline 
(PBS) containing 120 mM sucrose for 20 min, permeabilized with 0.25% Triton-X-100 in PBS for 10 
min and blocked for 2 h in 10% normal goat serum (NGS, Invitrogen) in PBS. Primary antibodies were 
incubated for 2 h in 10% NGS/PBS; secondary antibodies were incubated for 1 h in 10% NGS/PBS. 
Stained neuronal cultures were mounted in FluorSave Reagent (Calbiochem) and viewed on a Leica 
TCS SPE confocal microscope. Digital pictures were captured with Leica Software (LAS AF) and 
identically processed with ImageJ software (Abramoff, 2004). In order to label surface HA-GB1b-eGFP 
protein, neurons were stained with mouse anti-HA antibodies (1:500, Covance) prior to 
permeabilization. Total HA-GB1b-eGFP protein was labeled with rabbit anti-eGFP antibodies (1:500, 
Molecular Probes) following permeabilization. Internalized HA-GB1b-eGFP protein was labeled as 
follows: HA-GB1b-eGFP protein at the cell surface of living neurons was labeled prior to application 
of the treatment protocol by incubation with rabbit anti-HA antibodies (1:50, Immunology 
Consultants Laboratory) for 30 min at 37°C / 5% CO2. Following application of the treatment protocol, 
anti-HA antibodies were removed from HA-GB1b-eGFP remaining at the cell surface by an acid wash 
(2 min wash in Neurobasalmedium pH 2.0 on ice, followed by intensive washing with 
Neurobasalmedium pH 7.4 on ice). Following fixation and permeabilization, anti-HA antibodies 
bound to internalized HA-GB1b-eGFP were labeled with fluorophore-conjugated secondary anti-
rabbit antibodies. An appropriate number of neurons were stained with secondary anti-rabbit 
antibodies without permeabilization as a control for the acid wash. Secondary antibodies were: Alexa 
Fluor 488 goat anti-mouse, Alexa Fluor 568 goat anti-mouse, Alexa Fluor 488 goat anti-rabbit, Alexa 
Fluor 568 goat anti-rabbit (1:500; Molecular Probes). All steps were performed at room temperature 
unless indicated differently. The fluorescent intensity of labeled HA-GB1b-eGFP proteins was 
measured on the soma of transfected neurons and visualized in single optical planes using ImageJ 
software. For quantification of surface HA-GB1b-eGFP protein levels, fluorescent intensity of surface 
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HA-GB1b-eGFP was normalized to the total HA-GB1b-eGFP fluorescent intensity. Statistical analysis 
was performed with Graph Pad Software. For each statistical analysis independent sample groups 
were analyzed. 
 
4.1.3.4 Co-Immunoprecipitation 
Brain membranes from BALB/c mice were prepared as follows. Whole brains were polytron-
homogenized in HEPES buffer (4 mM HEPES pH 7.4, 320 mM sucrose, 1 mM EDTA, 1 mM EGTA) 
containing Complete Protease Inhibitor Cocktail (Roche) and centrifuged for 10 min at 1000 x g. 
Samples were kept at 4°C throughout the procedure. Supernatants were collected and 
ultracentrifuged for 30 min at 48000 x g. The resulting pellets (P2) containing the membrane fraction 
were solubilized in RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% deoxycholate) 
and were centrifuged for 30 min at 10000 x g to remove insoluble material. Supernatants were 
precleared by 3 h incubation with protein G-agarose beads (Roche). Anti-GABAB1 antibody 174.1 
(Malitschek, 1998) and anti-GABAB2 antibody (Chemicon) respectively, were added to the precleared 
lysates and incubated for 1 h followed by overnight incubation with protein G-agarose beads. Rabbit 
and guinea pig serum were used as a control. Immunoprecipitated complexes were washed 
extensively with RIPA buffer, separated by SDS-page and probed with an anti-CaMKIIα antibody 
(1:1000, Santa Cruz). 
 
4.1.3.5 GST-fusion proteins 
To generate GST-GB1 the full-length carboxyl-terminus of GABAB1 (amino acids 857–960) was 
amplified by PCR from rat GABAB1 cDNA (Kaupmann, 1997), digested with BamHI and XhoI, and 
subcloned in-frame into pGEX-4T-1 fusion vector (GE Healthcare). GST-fusion protein expression 
vectors containing alanine substitutions of serine or threonine residues in the GABAB1 carboxyl-
terminus (GST-GB1S867A, GST-GB1T869A, GST-GB1T872A and GST-GB1T869A/T872A) were 
generated by overlapping PCR from GST-GB1. To generate GST-GB2 the full-length carboxyl-terminus 
of GABAB2 (amino acid 745-940) was amplified by PCR from rat GABAB2 cDNA (Kaupmann, 1998b), 
digested with BamHI- and EcoRI and subcloned in-frame into pGEX-4T-1. GST-fusion proteins were 
expressed in E. coli BL21 (DE3) competent cells. Expression of the fusion-proteins was induced by 
1mM isopropyl 1-thio-β-D-galactopyranoside (IPTG) for 4 h. Cells were lysed by sonication and GST-
fusion proteins were purified by incubation with Glutathione Sepharose 4B (Amersham Biosciences) 
overnight at 4°C and washed with PBS. 
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4.1.3.6 Pull-Down assay 
Whole-brain lysates from BALB/c mice were prepared by polytron-homogenization in modified RIPA 
buffer (50 mM Tris-HCl  pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5% Triton X-100) containing 
Complete Protease Inhibitor Cocktail. Lysates were cleared by centrifugation at 15700 x g for 30 min 
at 4°C and incubated for 4 h with GST-fusion proteins immobilized on sepharose beads. Following 
extensive washing in RIPA buffer, isolated proteins were eluted by boiling in Laemmli buffer, 
separated by SDS-page and probed with anti-CaMKII antibody (1:5000, BD Biosciences). 
 
4.1.3.7 In vitro kinase assay 
GST-fusion proteins immobilized on sepharose beads were phosphorylated with recombinant CaMKII 
(New England Biolabs) or the cytosolic fraction (S2) of whole-brain extracts prepared from BALB/c 
mice by polytron-homogenization in HEPES buffer (brain membrane preparation above). 
Recombinant CaMKII was activated in phosphorylation buffer for 10 min at 30°C, according to the 
manufacturer’s instructions. For whole-brain extracts the following phosphorylation buffer was used: 
20 mM HEPES pH7.4, 1.7 mM CaCl2, 0.1 M dithiothreitol, 10 mM MgCl2, 1.6 mM cold ATP. For each 
phosphorylation reaction, 20 μg GST fusion-protein was incubated with recombinant CaMKII (500 
units) or whole-brain extract (50 μg) in the appropriate phosphorylation buffer and in the presence 
of 1 μl [γ-32P]-ATP (3000Ci/mmol) for 30 min at 30°C. Free [γ-32P]-ATP was removed by extensive 
washing with ice-cold phosphorylation buffer. To inhibit CaMKII activity, whole-brain extracts were 
preincubated with 10 μM KN-93 for 20 min at 4°C. Phosphorylated GST-fusion proteins were either 
separated by SDS-page and subjected to autoradiography or subsequently used for RP-HPLC and ESI-
MS/MS analysis. 
 
4.1.3.8 Reverse phase-high pressure liquid chromatography (RP-HPLC) 
For HPLC analysis, 20 μg of phosphorylated GST-fusion protein was digested with the endoproteinase 
Lys C (Wako Chemicals) followed by a second digestion with trypsin (Promega). Digestion was 
stopped by adding TFA to 0.1% (v/v) final concentration (TFA, Applied Biosystems). Insoluble material 
was removed by centrifugation (12,000 rpm, 5 min) and the supernatant was subjected to RP-HPLC 
on Vydac C18 reverse-phase columns (218TP52, 2.1 x 250 mm; Grace Vydac) connected to a Hewlett 
Packard 1090 HPLC system. Bound peptides were eluted at 150 l/min with a linear gradient from 
0.1% TFA/2% acetonitrile to 0.09% TFA/75% acetonitrile during 60 min. The effluent was monitored 
at 214 nm. Fractions were collected at 1 min intervals. The phosphorylated peptides in the fractions 
were located by liquid scintillation counting. 
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4.1.3.9 Electro spray ionization mass spectrometry (ESI-MS/MS) 
The radioactively labeled peptides were analysed by capillary liquid chromatography tandem MS 
(LC/MS/MS) using a set up of a trapping 300SB C-18 column (0.3x50mm) (Agilent Technologies) and a 
separating column (0.1x100mm) that had been packed with Magic 300Å C18 reverse-phase material 
(5 μm particle size, Michrom Bioresources Inc.). The columns were connected on line to an Orbitrap 
FT hybrid instrument (Thermo Finnigan). A linear gradient from 2 to 80% solvent B (0.1% acetic acid 
and 80% acetonitrile in water) in solvent A (0.1% acetic acid and 2% acetonitrile in water) in 85 min 
was delivered with a Rheos 2200 pump (Flux Instruments) at a flow rate of 100 μl/min. A pre-column 
split was used to reduce the flow to approximately 100 nl/min. The eluting peptides were ionized at 
1.7 kV. The mass spectrometer was operated in a data-dependent fashion. The precursor scan was 
done in the Orbitrap set to 60,000 resolutions, while the fragment ions were mass analysed in the 
LTQ instrument. A top five method was run so that the five most intense precursors were selected 
for fragmentation. The MS/MS spectra were then searched against the NCBI non-redundant 
databank using TurboSequest or Mascot software (Perkins, 1999, Gatlin, 2000). 
 
4.1.4 Results 
 
4.1.4.1 Glutamate-induced decrease of cell surface GABAB receptors is NMDA 
receptor dependent 
It was recently described that glutamate controls the availability of cell surface GABAB receptors in 
cortical neurons by promoting degradation of endocytosed receptors (Vargas, 2008). However, 
identification of the glutamate receptors and signaling cascades involved in this regulation has been 
lacking. We addressed the mechanism by which glutamate decreases the level of cell surface GABAB 
receptors in cultured neurons using a pharmacological approach. Abundant cell surface expression of 
GABAB1b was observed following co-transfection of primary hippocampal neurons with GABAB1b and 
GABAB2 expression constructs (HA-GB1b-eGFP and Myc-GB2, respectively). Surface expression was 
monitored by staining living cells with antibodies directed against the N-terminal HA-tag prior 
permeabilization (Figure 1A). Total HA-GB1b-eGFP levels were detected by anti-eGFP 
immunostaining following permeabilization of transfected cultures (Figure 1B). To quantify the level 
of surface GABAB1b between different treatments, surface HA-GB1b-eGFP staining was normalized to 
total HA-GB1b-eGFP. Upon glutamate treatment (50 μM for 30 min in the presence of 5 μM glycine), 
surface GABAB1b levels were significantly reduced to 41% of control (Figure 1A and B). Preincubation 
of neurons with the NMDA receptor antagonist APV (100 μM for 2 hours) prevented this glutamate-
induced decrease in surface GABAB1b (Figure 1A und B). This indicates that activation of NMDA 
receptors is critical for decreasing surface GABAB1b levels. We next tested whether direct activation of 
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NMDA receptors is sufficient to decrease surface GABAB1b levels. Following a short pulse of NMDA 
application (75μM NMDA for 3 min in the presence of 5μM glycine) and recovery in conditioned 
medium for 27 min, surface GABAB1b levels were significantly reduced to 28% of control levels (Figure 
1A and B). We examined whether the decrease of surface GABAB1b levels after glutamate and NMDA 
treatment is caused by the removal of receptors from the cell surface. While basal endocytosis of 
surface GABAB1b was detectable under control conditions, the pool of endocytosed GABAB1b was 
visibly increased upon glutamate and NMDA treatment. Endocytosis was prevented by preincubation 
with APV (Figure 1C). In conclusion, these findings indicate that glutamate reduces the availability of 
cell surface GABAB receptors by promoting internalization and that this process is dependent on the 
activation of NMDA receptors. 
 
4.1.4.2 NMDA receptor-induced decrease of cell surface GABAB receptors is 
mediated through CaMKII 
We assessed whether Ca2+-influx through NMDA receptors is critical for the regulation of surface 
GABAB receptor levels by glutamate. In the presence of the extracellular Ca
2+-chelator EGTA, 
glutamate failed to significantly reduce GABAB1b surface levels in transfected hippocampal neurons 
(normalized surface GABAB1b: glutamate, 34 ± 6.4% of control, n = 10, ***p < 0.001; glutamate + 
EGTA, 79 ± 6.0% of control, n = 10, p > 0.05; mean ± SEM, one-way ANOVA followed by Dunnet post-
hoc test). CaMKII can be activated by the Ca2+ elevation following NMDA receptor activation in the 
postsynaptic cell. We therefore investigated whether CaMKII activation is required for the NMDA 
receptor induced decrease in cell surface GABAB receptors. Upon preincubation of primary 
hippocampal neuronal cultures with the CaMKII inhibitor KN-93, glutamate (Figure 2A) and NMDA 
(Figure 2B) failed to reduce surface GABAB1b levels. These experiments demonstrate that CaMKII 
activation by NMDA receptors is involved in controlling GABAB receptor levels at the cell surface. 
 
4.1.4.3 CaMKII binds and phosphorylates GABAB receptors 
We next investigated whether CaMKII can associate with GABAB receptors. We found that rabbit 
anti-GABAB1 or guinea pig anti-GABAB2 antibodies co-immunoprecipitated CaMKII from purified 
mouse brain membranes. As a control, rabbit and guinea pig sera did not precipitate CaMKII (Figure 
3A). Furthermore GST pull-down assays were used to demonstrate the association of CaMKII with 
GABAB receptors. As the carboxyl-termini of GABAB1 and GABAB2 are relatively large domains, in 
contrast to the intracellular loops, they represent the most likely targets for modification by kinases 
(Fairfax, 2004). GST-fusion proteins containing the entire carboxyl-terminus of GABAB1 (GST-GB1) or 
GABAB2 (GST-GB2) were generated. CaMKII from whole-brain lysates was predominantly binding to 
GST-GB1, and to a lesser extent to GST-GB2 (Figure 3B). In vitro phosphorylation assays were 
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performed to further evaluate the phosphorylation of GABAB receptor carboxyl-termini by CaMKII. 
The GST-fusion proteins were incubated with [γ-32P]-ATP and recombinant CaMKII for 30 min at 30°C 
and resolved by SDS-PAGE. CaMKII-dependent phosphorylation was detected by autoradiography 
and was observed on GST-GB1 but not GST-GB2 or GST alone (Figure 3C). The degradation of the 
GST-GB2 fusion protein seen by Coomassie blue staining is consistent with earlier reports from other 
laboratories (Couve, 2002). Our findings indicate that CaMKII is associated with heteromeric GABAB 
receptors in the brain, and specifically phosphorylates the carboxyl-terminus of GABAB1. 
 
4.1.4.4 Identification of a CaMKII phosphorylation site within the carboxyl-terminal 
of GABAB1 
According to phosphorylation prediction programs, the carboxyl-terminus of GABAB1 contains a 
number of putative CaMKII phosphorylation sites (Pearson, 1985). To identify residues that are 
phosphorylated by CaMKII, proteolytic digests of in vitro phosphorylated GST-GB1 were analyzed by 
reverse-phase high-performance liquid chromatography (RP-HPLC) combined with electro spray 
ionization mass spectrometry (ESI-MS/MS). GST-GB1 was phosphorylated by recombinant CaMKII in 
the presence of [γ-32P]-ATP and digested by LysC and trypsin. Resulting peptides were separated by 
RP-HPLC analysis (Figure 4A, upper panel) and fractions collected at 1 min intervals. The majority of 
the radiolabel eluted in a single peak in fraction 54 (Figure 4A, lower panel), which was subjected to 
ESI-MS/MS analysis. An abundant phosphorylated peptide corresponding to residues 863-884 of the 
GABAB1 carboxyl-terminus was identified (GEWQpSETQDTMK) and phosphorylation was assigned to 
serine 867 (Figure 4B). Mutational analysis of the GST-GB1 fusion protein revealed that serine 867 is 
the only phosphorylation site in the carboxyl-terminus of GABAB1 that is phosphorylated by 
recombinant CaMKII (Figure 4C). Specifically, no phosphorylation was observed with GST-GB1S867A, 
which contains a S867 to alanine. Moreover, substitution of threonine 869 and/or threonine 872 
with alanine (GST-GB1T869A, GST-GB1T872A and GST-GB1T869A/T872A) did not prevent 
phosphorylation of the GST fusion proteins. By combining different approaches, we have shown that 
recombinant CaMKII is specifically phosphorylating GABAB1867. 
 
4.1.4.5 Endogenous CaMKII phosphorylates serine 867 
Next we tested whether serine 867 within the carboxyl-terminus of GABAB1 is phosphorylated by 
kinases in brain extractions. GST-GB1 was incubated with the cytosolic fraction of whole brain 
extracts in the presence of [γ-32P]-ATP and proteolytic peptides were separated by RP-HPLC (Figure 
5). Similar to phosphorylation by recombinant CaMKII, the majority of radiolabel eluted in a single 
peak following from the reverse-phase column (Figure 5A). ESI-MS/MS analysis demonstrated that 
the GABAB1 carboxyl-terminal peptide GEWQSETQDTMK was a major constituent of the radiolabeled 
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fraction. Due to low phosphorylation stoechiometry obtained with endogenous brain kinases direct 
phosphorylation of serine 867 could not be demonstrated. However, in phosphorylation experiments 
with brain extracts and GST-GB1S867A, the RP-HPLC fraction containing the mutated peptide 
GEWQAETQDTMK did not reveal any radiolabel (Figure 5B). Moreover, when GST-GB1 was 
phosphorylated with brain extract in the presence of the CaMKII inhibitor KN-93, no radiolabel was 
detected in the RP-HPLC fraction containing peptide GEWQSETQDTMK (Figure 5C). Thus, our findings 
indicate that CaMKII in whole brain extracts phosphorylates serine 867 in the carboxyl-terminus of 
GABAB1. 
 
Finally, we addressed whether phosphorylation of serine 867 participates in the reduction of surface 
GABAB receptors upon NMDA receptor activation. Primary hippocampal neurons were transfected 
with a GABAB1b mutant containing a substitution of serine 867 with alanine (HA-GB1bS867A-eGFP) 
together with Myc-GB2. Surface expression was monitored by staining living cells with antibodies 
directed against the N-terminal HA-tag prior to permeabilization and normalized to total 
GABAB1bS867A levels detected by anti-eGFP immunostaining following permeabilization (Figure 6A). 
Quantitative analysis revealed that neither glutamate nor NMDA application was able to promote 
GABAB1bS867A internalization (Figure 6B). In conclusion, our findings indicate that NMDA receptor 
activation controls surface GABAB receptor levels through CaMKII-dependent phosphorylation of 
serine 867 within the carboxyl-terminus of the GABAB1 subunit. 
 
4.1.5 Discussion 
 
The regulation of synaptic transmission depends on the availability of neurotransmitter-receptors at 
the cell surface. Therefore it is important to understand the mechanisms that regulate the trafficking 
of receptors to and from the plasma membrane. Contradicting results have been reported regarding 
the regulation of surface GABAB receptor levels. Using different cell culture systems, it was shown 
that basal endocytosis and recycling takes place (Grampp, 2007, Vargas, 2008, Wilkins, 2008). 
However, although the rate of recycling was reported to be increased in the presence of agonist, the 
total amount of cell surface GABAB receptors stayed unchanged (Grampp, 2007, Grampp, 2008, 
Vargas, 2008). More importantly, new evidence suggested that surface GABAB receptor levels were 
decreased in the presence of glutamate (Vargas, 2008). In the present work, we aimed to identify the 
glutamate receptor type responsible for regulating surface GABAB receptor levels as well as to 
characterize the underlying molecular mechanism. 
Our results confirm previous findings which describe reduction of surface GABAB receptors upon 
application of glutamate. Further, we identified the NMDA receptor as the glutamate receptor type 
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responsible for decreasing surface GABAB receptor levels. We demonstrate that GABAB receptors are 
internalized upon stimulation with glutamate or NMDA. In a recent report it was shown that 
glutamate stimulation may lead to proteolytic degradation of constitutively internalized GABAB 
receptors (Vargas, 2008). However, in contrast to the findings presented in our study, the authors did 
not detect increased levels of internalized receptors. This discrepancy could be caused by different 
experimental conditions. 
Preincubation of neurons with an NMDA receptor antagonist prevented the glutamate-induced 
reduction of surface GABAB receptor levels, ruling out that other glutamate receptors directly 
regulate surface GABAB receptor levels. However, other glutamate receptors, in particular AMPA 
receptors, are likely to contribute to the NMDA receptor-mediated effect. NMDA receptor activation 
is voltage dependent, requiring removal of the Mg2+ block by depolarization. Under physiological 
conditions this is primarily mediated by AMPA receptor activation. It is expected that there is 
sufficient basal activity in primary hippocampal neuronal cultures allowing for direct NMDA receptors 
activation by NMDA. In conclusion, our results demonstrate that NMDA receptor activation is 
essential and sufficient to reduce GABAB surface receptors, however modulatory roles of other 
glutamate receptors cannot be ruled out. 
NMDA receptors are localized at the postsynaptic density (PSD) of dendritic spines where their 
activation allows Ca2+ and Na+ to enter the spine. Glutamate failed to reduce surface GABAB 
receptors in the presence of extracellular EGTA, which implicates a crucial role for the Ca2+ influx 
following NMDA receptor activation. CaMKII is an established target downstream of NMDA receptor 
activation. CaMKII is one of the most abundant serine/threonine kinases in the brain and is enriched 
in the PSD. It is activated by binding of Ca2+/Calmodulin (Bennett, 1983, Kennedy, 1983) and 
subsequent autophosphorylation (Malenka, 1989b, Bayer, 2001). The GABAB receptor is known to be 
localized predominantly perisynaptically (Kulik, 2006, Guetg, 2009) and therefore in the vicinity of 
PSD associated proteins. Since CaMKII is coupled to the activation of NMDA receptors in many 
physiological processes, it was tested whether CaMKII plays a critical role in NMDA induced surface 
reduction of GABAB receptors. Indeed, preincubation with a CaMKII inhibitor failed to decrease 
surface GABAB receptors. We show evidence that reduction of surface receptors is mediated trough 
phosphorylation of the GABAB receptor by CaMKII. Recent studies show that, upon glutamate 
application or LTP induction, increased levels of activated CaMKII are restricted to single spines and 
do not incorporate neighboring spines (Zhang, 2008, Lee, 2009) Therefore, glutamate- and NMDA-
induced reduction of surface GABAB receptors most likely occurs postsynaptically on glutamatergic 
synapses. 
We identified serine 867 within the carboxyl-terminus of GABAB1 (GABAB1S867) as a novel 
phosphorylation site that can be phosphorylated by recombinant as well as endogenous CaMKII. 
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Interestingly, the sequence around GABAB1S867 is not conform to the consensus sequence for 
CaMKII phosphorylation (Pearson, 1985). GABAB1S867 is located in the juxtamembrane domain which 
is recognized as a regulatory region for many transmembrane proteins, in particular receptor 
tyrosine kinases. However a similar regulatory role for the juxtamembrane domain in GPCRs has not 
been established yet. Although we cannot exclude the existence of additional CaMKII 
phosphorylation sites within other domains of GABAB1 or on GABAB2, mutational analysis 
demonstrates that GABAB1S867 is essential for glutamate-induced reduction of surface GABAB 
receptor levels.  Two other phosphorylation sites on the GABAB receptor are described; first, serine 
892 on the GABAB2 subunit (GABAB2S892) was shown to be phosphorylated by cyclic AMP-dependent 
protein kinase (PKA) (Couve, 2002) and secondly, serine 783 on the GABAB2 subunit (GABAB2S783) by 
5’AMP-dependent protein kinase (AMPK) (Scott, 2002, Hardie, 2007, Kuramoto, 2007). 
Functionally, both GABAB2S892 and GABAB2S783 phosphorylation lead to stabilization of surface 
GABAB receptors and enhance GABAB receptor functions (Couve, 2002, Fairfax, 2004, Kuramoto, 
2007). In contrast, our results demonstrate that phosphorylation of GABAB1S867 reduces surface 
GABAB receptor levels. Similar to CaMKII, AMPK is activated in response to Ca
2+-influx following 
neuronal activity. However in contrast to CaMKII activation, which is directly mediated by 
calmodulin/Ca2+, AMPK activation requires the activation of calmodulin-dependent kinase kinases, in 
particular CaMKKβ. Moreover, AMPK is activated in response to metabolic stresses that deplete 
neurons of ATP and increase ADP levels (Hawley, 2005, Witters, 2006, Hardie, 2007). Thus the 
availability of GABAB receptors at the plasma membrane is differentially modulated by the carboxyl-
terminal phosphorylation. 
While another report showed that stimulation with glutamate stabilizes GABAA receptors at the cell 
surface thereby promoting inhibition (Marsden, 2007) our results suggest that NMDA-induced 
decrease of GABAB surface receptors strengthens excitatory signals. The bidirectional effect of 
glutamate may operate on the fast acting inhibitory GABAA receptor to prevent overexcitation and 
neurotoxicity, whereas decrease of slow acting surface GABAB receptor may support memory 
formation and contribute to long term potentiation. 
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Figure 1. Glutamate-induced decrease of GABAB surface receptors is NMDA receptor dependent. A, Rat 
hippocampal neuronal cultures were cotransfected with HA-GB1b-eGFP and Myc-GB2 expression vectors and 
analyzed at DIV14. Surface GABAB1b (GB1b) proteins were labelled with anti-HA antibodies prior to 
permeabilization. Total GB1b protein was labelled with anti-eGFP antibodies after permeabilization. 
Treatment with 50 μM glutamate in the presence of 5 μM glycine for 30 min decreased surface GABAB1b 
levels. This decrease of surface GABAB1b was abolished when neurons were preincubated for 2 hours with 
100 μM APV, a NMDA receptor antagonist. Specific activation of NMDA receptors with 75μM NMDA and 
5μM glycine for 3 min followed by recovery in conditioned medium for 27 min was sufficient to reduce 
surface GABAB1b levels. Neurons were visualized with confocal microscopy and represented as single optical 
planes. B, Quantification of surface GABAB1b levels expressed as surface fluorescent intensity relative to total 
fluorescent intensity. Values for individual treatments were normalized to control. Normalized surface 
GABAB1b levels were significantly reduced after glutamate and NMDA treatment. No significant change was 
observed with glutamate treatment after preincubation with APV (control: 100 ± 11%, n = 10; glutamate: 41 
± 5%, n = 10; glutamate + APV: 132 ± 29%, n = 10; NMDA: 28 ± 5, n = 10). Data are presented as mean ± SEM. 
For statistical analysis one-way ANOVA, followed by Dunnet post-hoc test was performed; **p < 0.01, ***p < 
0.001. C, To assess internalization of surface GABAB1b, live cells were incubated with anti-HA antibodies for 30 
min at 37°C, washed and left untreated for another 30 min (control) or incubated with, glutamate, glutamate 
+ APV or NMDA. Basal constitutive internalization was observed under control conditions. After glutamate 
treatment the rate of GABAB1b internalization was visibly increased. Preincubation with APV prevented 
glutamate-induced internalization of GABAB1b above control levels. Specific activation of NMDA receptors 
with NMDA was sufficient to increase internalization of GABAB1b. Maximum projections of representative 
neurons visualized with confocal microscopy are shown. Scale bar = 15μm. 
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Figure 2. CAMKII is required for the NMDA receptor-induced decrease of surface GABAB receptors. 
Rat hippocampal neuronal cultures were co-transfected with HA-GB1b-eGFP and Myc-GB2 
expression vectors and analyzed at DIV14. Surface GABAB1b (GB1b) labelled with anti-HA antibodies 
prior to permeabilization were assessed relative to total GABAB1b expression. Values for individual 
treatments were normalized to control. Preincubation of neurons with the CaMKII inhibitor KN-93 
(10 μM) for 2 h prevented the reduction in surface GABAB1b levels following treatment with 
glutamate (control: 100 ± 12, n = 10; glutamate 24 ± 5, n = 10; glutamate + KN-93: 102 ± 29; n = 6;) 
or NMDA (control: 100 ± 14, n = 10; NMDA: 29 ± 9, n = 10; NMDA + KN-93: 86 ± 18, n = 6). Data 
were represented as mean ± SEM. For statistical analysis one-way ANOVA, followed by Tuckey 
post-hoc test was performed; *p < 0.05, **p < 0.01. 
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Figure 3. CaMKII is associated with GABAB receptors and phosphorylates residues within the 
carboxyl-terminal domain of GABAB1. A, Anti-GABAB1 (GB1) and anti-GABAB2 (GB2) antibodies co-
immunoprecipitated CaMKII from purified mouse brain membranes. Normal rabbit serum (serum 
rb) and normal guinea pig (serum gp) were used as control. B, Pull down assays with GST-fusion 
protein containing the entire carboxyl-terminus of GABAB1 (GST-GB1) or GABAB2 (GST-GB2). 
Immobilized GST-fusion proteins were incubated with whole brain lysates and washed in RIPA 
buffer. Interacting proteins were pulled-down by centrifugation, separated by SDS-PAGE and 
probed for CaMKII by Western blotting. Pull-down assays with glutathione beads alone or together 
with GST were used as a control. CaMKII was predominantly observed in samples pulled-down with 
GST-GB1 and to some extend also with GST-GB2. C, In vitro phosphorylation assays of GST-fusion 
proteins with recombinant CaMKII. GST, GST-GB1 and GST-GB2 were incubated with [γ-32P]-ATP in 
the presence or absence of recombinant CaMKII. Phosphorylated proteins were separated by SDS-
PAGE and exposed to autoradiography. Coomassie blue staining of the gel was used as loading 
control. Recombinant CaMKII specifically phosphorylated GST-GB1 but not GST-GB2 or GST alone. 
This demonstrates that residues within the carboxyl-terminal domain of GABAB1 are accessible for 
phosphorylation by CaMKII. 
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Figure 4. Identification of serine 867 as a CaMKII phosphorylation site on GABAB1. A, Reverse-phase 
high-performance liquid chromatography (RP-HPLC) analysis of GST- GABAB1 carboxyl-terminus 
fragment (GST-GB1) that had been phosphorylated by recombinant CaMKII. GST-GB1 and digested 
with endoproteinase LysC and trypsin.  GST-GB1 elution of peptides monitored at 214 nm (A) and 
and liquid cintillation counting of the fractions collected during chromatography (C). The asterisk 
marks the elution of the phosphopeptide in fraction 54. B, Fragmentation spectrum of the doubly 
charged 768.29 Da precursor from the radioactively labelled peptide of fraction 54 of GST-GB1. The 
fragmentation pattern is in accordance with the predicted MS/MS spectrum for the 
phosphopeptide GEWQpS867ETQDTMK. The y- and b-ions that match the GEWQpS867ETQDTMK 
sequence are labelled. Phosphorylated ions are marked by an asterisk. C, In vitro phosphorylation 
of GST fusion proteins with recombinant CaMKII in the presence of [γ-32P]-ATP. Samples were 
separated by SDS-page and exposed to autoradiography. Substitution of serine 867 with alanine in 
GST-GB1S867A prevented phosphorylation by CaMKII. In contrast, GST fusion proteins with 
substitutions of other phosphorylable residues in proximity of serine 867 were still phosphorylated 
(GST-GB1T869A, GST-GB1T872A and GST-GB1T869A/T872A). Coomassie blue stain was used as 
loading control. 
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Figure 5. Endogenous CaMKII phosphorylates GABAB1S867. (A-C) GST-fusion proteins were 
incubated with the cytosolic fraction of whole mouse brain extracts in the presence of [γ-32P]-ATP 
and analyzed by RP-HPLC. Elution profiles are shown on the top and scintillation graphs on the 
bottom. The carboxyl-terminal GABAB1 peptide GEWQSETQDTMK was identified by ESI-MS/MS as a 
major constituent of a highly phosphorylated fraction (asterisk) of the GST-GB1 effluent (A). The 
corresponding fraction of the GST-GB1S867A effluent (arrow head) containing peptide 
GEWQAETQDTMK with a substitution of alanine for serine 867 did not get phosphorylated (B). 
Following phosphorylation of GB1-GST in the presence of KN-93 no radiolabel was detected in the 
fraction containing GEWQSETQDTMK (arrow head) (C).  
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Figure 6. Mutation of serine 867 in GABAB1 prevents NMDA receptor-induced down-regulation. A, 
Rat hippocampal neuronal cultures were cotransfected with HA-GB1bS867A-eGFP and Myc-GBR2 
expressing vectors. At DIV14, neurons were treated with glutamate (50 μM for 30 min at 37°C in 
the presence of 5μM glycine) or NMDA (75 μM for 3 min at in the presence of 5μM glycine, 
followed by recovery in conditioned medium for 27 min). Surface GABAB1bS867A protein was 
labelled prior to permeabilization with anti-HA antibodies. Total GABAB1bS867A protein was 
labelled after permeabilization with anti-eGFP antibodies. Neurons were visualized with confocal 
microscopy and represented as single optical planes. Scale bar = 15μm. B, Glutamate as well as 
NMDA did not induce any significant changes in surface levels of GABAB1bS867A. (control: 100 ± 22, 
n = 10; glutamate: 108 ± 22, n = 10; NMDA: 109 ± 21, n = 9). Data were represented as mean ± SEM. 
For statistical analysis one-way ANOVA, followed by Dunnet post-hoc test was performed. 
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4.2 Supplemental results 
  
4.2.1 Analysis of the GABAB1 subunit carboxyl-terminus for phosphorylation targets 
 
Carboxyl-terminals are the most promising intracellular target domains for GABAB receptor 
phosphorylation. In the case of mGluRs, which are closely related to GABAB receptors, a growing 
body of literature suggests that phosphorylation happens at the carboxyl-terminal region and 
regulates the mGluRs function. Schaffhauser et al. discovered that mGluR2 phosphorylation by PKA 
at serine 843 inhibits its function, probably due to coupling of mGluR2 to GTP-binding proteins 
(Schaffhauser, 2000). Later, the same group stated that PKA inhibits the function of multiple mGluR 
subtypes by a similar mechanism (Cai, 2001). Other groups have rather attributed that effect to the 
PKC activity (Macek, 1998, Kim, 2005). However, all these works have as as common ground 
phosphorylation sites located in the carboxyl-terminal region of the mGluRs and an effect on the 
mGluRs function.  
The carboxyl-termini of the GABAB receptor subunits are large domains and therefore, most likely 
include possible phosphorylation targets (Fairfax, 2004). The GABAB1 carboxyl-terminal starts after 
the methionine 856, covering the amino acids from the arginine 857 (R857) up to the lysine 960 
(K960) (Kaupmann, 1997). In Table 1, the predicted phosphorylation sites for the GABAB1 carboxyl-
terminal are summarized. There are six serines, four threonines and no tyrosine. None of the 
predicted sites was shown to be phosphorylated, but the serine 923 appeared to influence the S917 
phosphorylation (Couve, 2002). The preliminary analysis of that carboxyl-terminal was done using 
many consensus motifs from literature (Table 2). Consensus motifs are the conserved kinase 
recognition sequences. The findings were validated further by state-of-the-art phosphorylation site 
prediction programs (Table 3). The phosphorylation site prediction has proven, due to its accuracy, to 
be of great importance for phosphorylation site research. The predicted sites are equally distributed 
and not concentrated at a certain region of the GABAB1 carboxyl-terminal. Therfore, there is no 
specific region on which to focus thus the first in vitro phosphorylation experiments have to be done 
with the full-length GABAB1 carboxyl-terminal GST-fusion protein. 
  GABAB1 C-terminus 
R857-RRLITRGEWQ  SETQDTMKTG  SSTNNNEEEK  SRLLEKENRE  LEKIIAEKEE  RVSELRHQLQ  
SRQQLRSRRH  PPTPPDPSGG  LPRGPSEPPD  RLSCDGSRVH  LLYK -K960  
 
Table 1. Summary of the literature and phosphorylation programs predicted phosphorylation  
targets in the GABAB1 carboxyl-terminus. Predicted threonine phosphorylation sites (T) are highlighted in  
red and serines (S) in blue. The coiled-coil domains are underlined. 
GABAB1 carboxyl-terminus
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Kinase Published consensus motif Reference 
AMPK M or L/F/I/V-(X)2-S
*/T*-(X)3-M/L/F/I/V Scott, 2002  
CaMKII R-(X)2- S*/T* Hanson, 1989 
GSK3 S*-(X)2-S*, S*/T*-(X)3/4-S/P/T-P Ptacek, 2005 ,  Doble, 2007 
PKA R/K-X- S*/T* Pearson, 1991 
PKB R-X-R-(X)2- S*/T* Fayard, 2005 
PKC S*/T*-(X)1/2-K, K-(X) 1/2- S*/T* Wera, 1999 
              Table 2. Listing of the in literature found diverse kinase consensus motifs.  
 
 
Program URL Number Literature 
ELM 1 Puntervoll, 2003 
             An EXCEL-based method 
              to search for potential  
             Ser/ Thr-phosphorylation 
                   sites in proteins 
2 Wera, 1999 
Motif Scan 3 Liu, 2008 
Net Phos 2.0 4 Huang, 2005 
Net PhosK 1.0 5 Xue, 2005 
PhosphorylationElm 6 Diella, 2004 
PhosphorylationSite Plus 7 Rush, 2005 
Prediction of phosphorylation sites 
using SVMs 
8 Kim, 2004 
Pred Phospho 9 Wong, 2007 
Scansite 10 Obenauer, 2003  
URL Number URL Address 
1 http://elm.eu.org/links.html 
2 
http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6T5J-
3V5TKGB-6-
1&_cdi=5004&_user=946149&_orig=search&_coverDate=01%2F01%2F1998&
_sk=999419998&view=c&wchp=dGLbVzW-
zSkzS&md5=e62cdfd15745ad93fac409d29a9fa02b&ie=/sdarticle.pdf 
3 http://hits.isb-sib.ch/cgi-bin/PFSCAN 
4 http://www.cbs.dtu.dk/services/NetPhos/ 
5 http://www.cbs.dtu.dk/services/NetPhosK/ 
6 http://phospho.elm.eu.org/ 
7 http://www.phosphosite.org/homeAction.do 
8 
http://www.ncbi.nlm.nih.gov/pubmed/15231530?ordinalpos=3&itool=Entrez
System2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum 
9 
http://phosphovariant.ngri.go.kr/predphospho.htm?PHPSESSID=0e390b13ed
30d0beaf5a2d42896c993e 
10 http://scansite.mit.edu/ 
Table 3. Phosphorylation programs register and their citation in literature (upper part), the URL addresses from 
 the phosphorylation programs are listed in the lower part. 
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4.2.2 Glutathione S-tranferase fusion system 
 
The glutathione s-transferase (GST) fusion system is profiled as the optimal model to study 
phosphorylation of the GABAB receptors at the GABAB1 carboxyl-terminal. The GST fusion system 
expresses, purifies, and detects recombinant fusion proteins produced in E. coli. It relies on inducible, 
high-level gene expression of gene fragments as fusion proteins with a Schistosoma japonicum GST-
tag (Table 4.a). A fusion protein contains the GST-tag localized at the amino terminal and the protein 
of interest at the carboxyl-terminal. The GST fusion proteins are purified from bacterial lysates by 
means of affinity chromatography using immobilized glutathione (glutathione coated sepharose 
beads) while the impurities are removed by washing. Boiling the samples in Laemmli buffer or under 
mild, non-denaturing conditions using reduced glutathione elutes the GST fusion proteins from the 
immobilized glutathione. The GST fusion system has been used successfully in many applications 
including molecular immunology (Toye, 1990), the production of vaccines (Fikrig, 1990, Johnson, 
1989) and studies involving protein-protein (Kaelin, 1991) and DNA-protein (Chittenden, 1991) 
interactions. In this work, the GST-GB1 protein, including the full-length carboxyl-terminal of GABAB1 
(amino acids 857–960, see Table 4.b) was used.  
 
A first important hint, that a phosphorylation site on the GABAB1 carboxyl-terminal is located at a 
juxtramembrane site was given from the first in vitro phosphorylation experiments using the GST-
GB1 fusion protein and its truncations. These GST-GB1 fusion proteins were gradually truncated from 
their carboxyl-terminal. They were phosphorylated using native and purified kinases. GST-GB1Δ1 
(Table 4.c) and GST-GB1Δ2 (Table 4.d), the two truncated forms were generated by PCR from GST-
GB1. The sense primer (5`-GTTCCGCGTGGATCCCGCAGG-3’) is the same for GST-GB1Δ1 and GST-
GB1Δ2. Conversly, the antisense is different for GST-GB1Δ1 (5`-TTTCTCGAGCTACTTCTCTTCCTCGTTGT 
T-3’) and GST-GB1Δ2 (5’-TTTCTCGAGCTATGGGGGGTGGCGCCG TGA -3’). The generated PCR 
fragments were digested with BamHI- and XhoI and subcloned in-frame into the pGEX-4T-1 plasmid. 
The truncated GST-fusion proteins were expressed, induced and lysed as previously described for the 
GST-GB1 fusion proteins. 
The GST fusion system enabled the discovery of a new phosphorylation site on the GABAB receptors 
by in vitro phosphorylation and HPLC-MS analysis. On the other hand, the interaction between the 
responsible kinase with the GABAB receptor can be showed in pull-down assay. But one must keep in 
mind that the GST fusion system is artificial and a simplifying model. Indeed, this technique does not 
take into account phosphorylation influencing factors like folding of the carboxyl-termini or 
interaction with binding partners. Nevertheless, the GST fusion system enables the generation of 
large amounts (important for further analysis steps like high pressure liquid chromatography) of a 
model protein comprising most of the phosphorlylation sites of the native GABAB1carboxyl-terminal. 
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4.2.3  In vitro phosphorylation using purified or endogenous kinases 
 
In vitro phosphorylation enables the study of kinase activity under experimental conditions. The 
target protein GST-GB1 mimics the GABAB1 carboxyl-terminal in the in vitro phosphorylation assay. 
The GST-GB1 is bound to the immobilized glutathione. The kinases can be purified and easily 
purchased whereas active native kinases can be obtained from native tissue. In the following work 
started with the native kinases obtained from mouse brain lysate. Importantly, in order to properly 
activate the native kinases, the right buffer conditions are fundamental.  Indeed, they ought to 
activate as many kinases as possible and block as few as possible. Kim et al. published 2005 data on a 
buffer that was able to activate PKC (Kim, 2005). This buffer contains basic kinase buffer 
components; CaCl2, MgCl2 and ATP where ATP does not only activate the kinase but also primarly 
serves as the phosphate group source. The total concentration of ATP in an in vitro kinase essay is 
around 1.6 mM. The application of only of 1 μl [γ-32P]-ATP (3000Ci/mmol) is enough to radioactively 
tag the phosphorylated protein. To get rid of the unnecessary not incorporated [γ-32P]-ATP and to 
finally stop the phosphorylation reaction, the immobilized beads were washed with the ice-cold 
phosphorylation buffer. Afterwards, the samples were eluted by boiling in Laemmli buffer containing 
phosphatase inhibitors. The samples were next separated by SDS-PAGE. The phosphorylated proteins 
were revealed on X-ray film exposed to the dried polyacrylamide gel. In vitro phosphorylation 
experiments with native kinases show a clear phosphorylation of GST-GB1 proteins, whereas the 
GST-tag alone stays unphosphorylated (Figure 7). To get an idea on the localization of the 
phsophorylation sites, the GST-GB1 carboxyl-terminal truncated forms GST-GB1Δ1 and GST-GB1Δ2, 
described above were used.  The truncated-GST-GB1Δ2 containing the GABAB1 carboxyl-terminal first 
a) GST-tag: 
MSPILGYWKI KGLVQPTRLL LEYLEEKYEE HLYERDEGDK WRNKKFELGL EFPNLPYYID GDVKLTQSMA IIRYIADKHN 
MLGGCPKERA EISMLEGAVL DIRYGVSRIA YSKDFETLKV DFLSKLPEML KMFEDRLCHK TYLNGDHVTH PDFMLYDALD 
VVLYMDPMCL DAFPKLVCFK KRIEAIPQID KYLKSSKYIA WPLQGWQATF GGGDHPPKSD LVPRGS 
Total protein length: 226 amino acids, 27 kDa long 
b) GST-GB1:  
GST-RRLITRGEWQ SETQDTMKTG SSTNNNEEEK SRLLEKENRE LEKIIAEKEE RVSELRHQLQ SRQQLRSRRH PPTPPDPSGG 
LPRGPSEPPD RLSCDGSRVH LLYK 
Total protein length: 330 amino acids, 35 kDa long 
c) GST-GB1Δ1:  
GST-RRLITRGEWQ SETQDTMKTG SSTNNNEEEK SRLLEKENRE LEKIIAEKEE RVSELRHQLQ SRQQLRSRRH PP 
Total protein length: 298 amino acids, 33 kDa long 
d) GST-GB1Δ2:  
GST-RRLITRGEWQ SETQDTMKTG SSTNNNEEEK 
Total protein length: 256 amino acids, 28 kDa long 
Table 4): Sequences of the GST-fusion protein; a) GST-Tag alone (GST-) from Schistosoma japonicum, b) GST-
GB1: Full length GABAB1 carboxyl-terminal (R857-K960) fused to the GST-tag, c) GST-GB1Δ1: The first fusion 
protein from the GST-GB1 protein with a 3’ end truncated carboxyl-terminal (R857-P928) and d)  the second 
one; GST-GB1Δ2 (R857-K887). 
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30 amino acids (coming from the amino terminus) and the GST-GB1Δ2 already showing a clear 
phosphorylation signal were both phosphorylated by native kinases (Figure 7). This experiment thus 
gave the first hint for the juxtramembrane position of a phosphorylation site on the GABAB1 carboxyl-
terminal. The protein loading amount was normalized by Coomassie blue staining of the gel (not 
shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In order to identify the active native kinases involved in the phosphorylation, the work was carried 
on with purified kinases as they yield to high phosphorylation levels. The alternative would have 
been to use kinase inhibitors althought problems with the inhibitors specificity can always emerge. 
For the exact identification of the phosphorylation site by HPLC and MS, the usage of purified kinases 
then seemed to be the better option. The purified kinases CaMKII, PKC and PKA were chosen due to 
their important role in the CNS. Repeating the in vitro phosphorylation of the GST-GB1 fusion protein 
using the three kinases unveiled an interesting finding. The GABAB1 carboxyl-terminal can be 
phosphorylated by the three kinases (Figure 8).  Interestingly, the GST-GB1Δ1 and GST-GB1Δ2 
truncations also were phosphorylated by the purified CaMKII, PKA and PKC (not shown). This 
observation indicates that native GABAB1 carboxyl-terminals contain phosphorylation sites for 
CaMKII, PKA and PKC and for the first two kinases the phosphorylation sites are positioned at the 
juxtamembrane. It cannot be excluded, although highly unlikely, that these phosphorylatation sites 
overlap, especially due to their different consensus motifs. 
The identification of several sites for instance by making alanine substitutions, would have been time 
consuming and a difficult task to undertake. The considerations of the HPLC/ MS technique are 
 
 
Figure 7. The in vitro phosphorylation of the GST-GB1 truncations GST-GB1Δ1 and GST-GB1Δ2 with native 
kinases. The truncations are indicated in the GST-GB1 sequence. As expected, GST-GB1 gets phosphorylated.  
Both truncations also get phsophorylated. The first 30 amino acids of the GABAB1 C-terminus were sufficient to 
get a phosphorylation signal.
56
  
limited and not suitable for the analysis of all the possible phosphorylation sites. The variety of 
different possible kinase phosphorylation sites demands the systematic analysis of a single 
phosphorylation site. That was the most promising and fastest way to find, under the given 
circumstances, a physiological relevant phosphorylation site. The kinase with the most potential was 
CaMKII.  Indeed, it has a consensus motif appearing in the proteolytic peptide fragments and most 
importantly, it is very abundant in the CNS. Additionnaly, indications from the literature (Vargas, 
2008) and from different unpublished electrophysiological experiments and localization studies 
predict a physiological relevant connection between CaMKII and GABA receptor.  All this information 
led to the decision of focusing all the efforts on CaMKII actions.  
 
 
 
 
 
 
 
 
 
4.2.4 High pressure liquid chromatography (HPLC) and Mass spectrometry (MS)  
 
The mass spectrometry (MS) measures the mass to charge ratio (m/z) of ions. The high pressure 
liquid chromatography (HPLC, also sometimes called high performance liquid chromatography) is a 
form of column chromatography used to separate, identify and quantify compounds. The HPLC 
consists of a column packed with a chromatographic material, generating a specific surface layer 
(stationary phase) and a pump that moves the analyte containing mobile phase through the column. 
A detector at the end records the elution of the analytes. The retention time varies depending on the 
interactions between the stationary phase, the molecules being analyzed and the solvents used. 
 
The combination of liquid chromatography and mass spectrometry allows the detection of analytes 
in the picomol range. It was made possible by the availability of the electro spray (ES) technology 
(Issaq, 2009). The electro spray technology is a technique that ejects the ions from a solvent 
containing the analyte(s) of interest. The electro spray disperses the liquid into a fine aerosol. The ion 
formation involves extensive solvent evaporation by mixing water with volatile organic compound 
solvents (e.g. methanol, acetonitrile). The first vacuum stage of a MS samples the aerosol through a 
 
 
Figure 8. The in vitro phosphorylation of GST-GB1 with the purified kinases CaMKII,PKA and 
PKC. All three kinases phosphosphorylate GST-GB1. This indicates that the GABAB1 carboxyl-
terminus could be a target for several kinases.
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capillary. The solvent evaporates from a charged droplet until it becomes unstable upon reaching its 
Rayleigh limit; the droplet size decreases, the charge to surface ratio increases.  Ions of equal charge 
repel each other and the droplet deforms and emits charged ions. During this process, the droplet 
loses a small percentage of its mass (an electron) along with a relatively large percentage of its 
charge. The ES technique is so mild that labile analytes remain intact after the electro spray 
ionisation (ESI) procedure (Bothner, 1998). For the analysis of phosphorylated peptides, reverse 
phase-high pressure liquid chromatography (RP-HPLC) is the chromatography of choice. In RP-HPLC, 
the solid phase support is modified by long saturated hydrocarbon chains. The analyte binds to the 
stationary phase via hydrophobic interactions. The analyte is dissolved in aqueous trifluoroacetic 
acid, the polar solvent. When the concentration of acetonitrile slowly increases during the gradient, 
adsorbed peptides elute sequentially from the stationary phase with increasing hydrophobicity. The 
detector records eluting peptides at 214 nm, while at 280 nm the aromatic amino acids containing 
peptide fragments can be detected.  
  To increase the stoichiometry of phosphorylation, at least 10μg of the target protein should 
be phosphorylated with a final ATP concentration of 20 μM. To facilitate the tracking of the 
phosphorylated peptides, the kinase reaction is carried out by spiking the ATP mixture with 1 μl of 
radioactive ATP (indicates the specific activity) to reach at least 10% phosphorylation of the protein 
of interest. In that experiment, however, we could not reach the desired phosphorylation 
stoichiometry using native kinases. Instead, we used purified, highly active CaMKII, to obtain 
reasonable phosphorylation. The peptide fragments are generated by a digestion with 
endoproteinases lys-c and trypsin (Jeno, 1995). The lys-c cleaves at the carboxyl-terminal end of 
lysine whereas the trypsin cleaves peptide bonds carboxyl-terminal of lysine and arginine. The rate of 
hydrolysis can be slowed down by acidic residue (glutamic acid or aspartic acid)_on either side of the 
cleavage site. A proline on the carboxyl-terminal of the cleavage site can even inhibit digestion by 
trypsin without affecting lys-c cleaving activity. The peptide fragments generated are usually 
between 5 to 30 amino acids longs. Very short peptides do not bind to the reverse-phase matrix 
while very long peptides tend to bind irreversibly to the column. In Table 5 the lys-c and trypsin 
digested peptides obtained from GST-GB1 are summarized. 
The liquid scintillation counting of the HPLC fragments unveils a strongly phosphorylated peptide. 
The MS analysis of this fraction yielded two peptides of 1439.61 Da and 1519.58 Da. The collision-
induced dissociation (CID) spectrum and databank searching showed that the two peptides are 
derived from the juxtamembrane position of GST-GB1 and comprise the unphosphorylated 
GEWQS867ETQDTMK (Figure 9.a) peptide and the phosphorylated peptide GEWQpS867ETQDTMK with 
a phosphorylation at the S867 (Figure 9.b). 
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Table 5. The digestion map of GST-GB1 for the combined application of the endoproteinases lys-c and 
trypsin and the MS spectrum of the phosphorylated S867 containing peptide. In the upper line the 
generated peptide fragment lengths are indicated. The negative charged amino acids (glutamic acids (E) 
and aspartic acids (D) slow down the tryptic hydrolysis rate at an arginine (R), the cursive number stands 
for the affected fragments. For that reason, the following fragment also contains two length numbers for 
respresenting uncompleted cleavage. The cleavage sites are indicated by bold letters (K and R). The 
fragment containing the phosphorylated S867, underlined in the sequence, starting with G233 and ending 
with K244, appeared in the MS analysis. 
GST-Tag: amino acids 0-226 
                   9    2            7        9      8         5/13   2  2 1                19                  
0-MSPILGYWKI   KGLVQPTRLL   LEYLEEKYEE   HLYERDEGDK   WRNKKFELGL   EFPNLPYYID   GDVKLTQSMA   
      9       5                   9   2                            14/16     5           5         6               6             6        5      4/10         
   IIRYIADKHN   MLGGCPKERA   EISMLEGAVL   DIRYGVSRIA   YSKDFETLKV    DFLSKLPEML   KMFEDRLCHK   
                            35        5   1 1                9    3    3                                                 
   TYLNGDHVTH   PDFMLYDALD   VVLYMDPMCL   DAFPKLVCFK   KRIEAIPQID   KYLKSSKYIA   WPLQGWQATF    
               21             6 
  GGGDHPPKSD   LVPRGS-226 
 
GABAB1 C-terminus: amino acids 227-330 
      3 1       4                              12                     10   2       4    3       4/7      5    3    5   6        4   2 1 
227-RRLI  TRGEWQS867ETQ  DTMKTGSSTN NNEEEKSRLL  EKENRELEKI  IAEKEERVSE  LRHQLQSRQQ  LRSRRHPPTP 
                14          8             7/15      6 
   PDPSGGLPRG  PSEPPDRLSC DGSRVHLLYK-330 
 
Figure 9. The electrospray ionization mass spectrometry (ESI-MS) spectra from (A) the unphosphorylated 
GEWQSETODTMK peptide fragment and (B) the phosphorylated GEWQpSETODTMK. A) S867 matches with 
collisional induced ions y8 and b5. All ions before y8 and b5 are identical in both spectra. B) The remaining y 
as well b ions have a 80 Da shift, indicating a phosphorylation at S867. The ESI-MS of the phosphorylated 
fraction revealed the phosphorylated peptide GEWQpS867ETQDTMK containing the serine 867 (S867) as 
phosphorylation site for CamKII. The doubly charged precursor (768.29 m/z) was subjected to 
fragmentation. The present y- and b-ions are match with the identified phosphorylated peptide. Ions 
showing a mass shift of 80 Da (mass of a phosphate residue). 
  
A B 
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4.2.5 The phosphospecific pS867 antibody 
 
After showing the phosphorylation of GST-GB1 at S867 by native CaMKII, the next step was to 
demonstrate that S867 can be phosphorylated in native GABAB1 subunits. This was done by 
generating a phosphospecific antibody pS867. This pS867 antibody specifically recognizes the 
phosphorylated S867 site. In the following chapter the generation and characterization of the pS867 
antibody will be discussed. The interesting findings of native S867 phosphorylation will be highlighted 
and the mechanism increasing its phosphorylation will be explained. Finally the preliminary 
immunohistochemical experiments with the pS867 antibody will be outlined. 
 
4.2.5.1 Generation of the pS867 antibody 
For the pS867 antibody generation, an S867 phosphorylated peptide ITRGEWQpS867EAQDT (Lamp, 
2001) was conjugated to the carrier protein keyhole limpet hemocyanin (KLH) to achieve an 
increased immunization. The sequence and phosphorylation of the phosphorylated peptide was 
verified by MS analysis. The phosphorylated peptide-KLH conjugate was emulsified with complete 
Freund’s adjuvant and injected subcutaneously in New Zealand rabbits four times at biweekly 
intervals. Additional injection of the peptide-KLH conjugate in Freund’s incomplete adjuvant boosts 
the immunization reaction. One week after the boost, the blood is collected from the central ear 
artery and is allowed to clot and retract at 37°C overnight. The serum is decanted and clarified by 
centrifugation at 2’500 rpm for 15 minutes. The antibody fraction is then purified by affinity 
chromatography on beads. For this, beads were equilibrated with the phosphorylated peptide-KLH 
conjugate dissolved in a PBS and NaCl solution. The beads were washed with PBS. The washed beads 
were loaded into a plastic column and washed again with PBS until the OD at 280 nm is 0. The elution 
of the antibodies was done with a mixture of 200 mM glycine at pH 2.8. The immunoglobulin-
containing fraction is identified by measuring the absorbance at 280 nm. The fractions were dialyzed 
against PBS at 4°C overnight. To absorb anti-non-phosphopetide antibody, the generated antibody 
solution is applied onto a column and equilibrated with the non-phosphopetide-KLH conjugate. The 
non-phosphorylated peptide ITRGEWQSEAQDT. The purified solution is then collected and its 
absorbance mesured on more time at 280 nm. The pS867 specificity was finally confirmed by ELISA 
where the antibody showed a strong affinity towards the phosphorylated peptide. 
 
4.2.5.2 Characterization of the pS867 antibody 
Additionally to the ELISA data, the specificity of the pS867 antibody was examined using the GST-GB1 
protein and its S867A substitution, phosphorylated by purified CaMKII. The pS867 antibody 
surprisingly does not recognize the unphosphorylated GST-GB1 proteins (Figure 10a, first lane).but 
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recognize the phosphorylated form of GST-GB1 protein (Figure 10a, second lane). Finally, in the last 
lane, a CaMKII phosphorylated GST-GB1S867A alanine mutant was loaded and the the pS867 
antibody was unable to recognize it (Figure 10a, third lane). The equal loading of GST-GB1 and GST-
GB1S867A protein amounts was ensured by GABAB1 antibody staining of the stripped blot (Figure 
10a, lower panel). The pS867 antibody fulfils the criteria of sequence and phosphorylation specificity 
and is then suitable for the further analysis of the S867 phosphorylation.   
Unfortunately, phosphorylation sites are often the target of several kinases. Luckily, the pS867 
antibody allows getting a quick and easy assessment of S867 phosphorylation by other kinases than 
CaMKII. Indeed, GST-GB1 phosphorylation by different purified kinases can be straightforwardly 
tested (Figure 10b). In the first lane, the unphosphorylated GST-GB1 protein was loaded and, as 
expected, no signal from the pS867 antibody was obtained (Figure 10b, first lane). As previously 
seen, the purified CaMKII phosphorylates the GST-GB1 at S867 (Figure 10b, second lane). 
Additionally, the purified PKA also phosphorylates the GST-GB1 protein at S867 (Figure 10b, third 
lane). However, PKC has been shown to phosphorylate the GST-GB1 protein (Figure 7), but not at the 
S867 site (Figure 40.b), fourth lane). The loading amount was normalized by GABAB1 antibody blotting 
(lower panel). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.5.3 In vivo phosphorylation of the GABAB1 isoform 
The results generated with the different versions of the recombinant GST-GB1 fusion proteins, clearly 
show, that S867 is a phosphorylation target on the GABAB1 subunits. The pS867 antibody finally 
Figure 10. Characterization of the pS867 antibody and the phosphorylation of S867 by CaMKII and PKA. A) 
To control the phosphorylation specificity of the antibody pS867, GST-GB1 fusion proteins were 
phosphorylated by CaMKII. The unphosphorylated GST-GB1 proteins are not recognized by the pS867 
antibody (first lane). The phosphorylated GST-GB1 proteins get phosphorylated (second lane). Finally the 
phosphorylated GST-GB1S867A does not get recognized by the pS867 antibody. The loading amount was 
normalized by staining the blot with a GABAB1 antibody (lower panel). B) The pS867 antibody allows 
determining which kinases could phosphorylate GST-GB1 at S867. The unphosphorylated GST-GB1 protein 
is not recognized (first lane). CaMKII as previously shown phosphorylates S867 (second lane). PKA also 
phosphorylates GST-GB1 at S867 (third lane); whereas PKC does not (fourth lane). 
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allows determining if native GABAB1 subunits are phosphorylated at S867. For that, an 
immunoprecipitation of the GABAB1 subunit from mouse brain lysate was done.  
The mouse brain lysate was prepared from adult wildtype Balb/C (WT). The brains are homogenized 
in 0.32 M Sucrose-HEPES buffer (0.32 M sucrose, 4 mM HEPES, 1 mM EDTA, 0.5 M EDTA pH 8, 1 mM 
EDTA, 0.5 M EGTA pH 8, complete protease inhibitor cocktail  and the phosphatase inhibitor cocktails 
1 and 2 (Sigma-Aldrich, St. Louis, MO). The lysates are centrifuged at 2900 g for 10min at 4°C to 
remove nucleic debris. Afterwards, the supernatant is ultracentrifuged for 30 min at 4°C at 48000 g. 
The pellets are solubilised in 3 ml RIPA buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-
40 (IGEPAL), 0.5 % DOC, and complete protease inhibitor cocktail,  and the phosphatase inhibitor 
cocktails 1 and 2). By sonication and centrifugation at 15’000 g the lysates are finally cleared. Loading 
of the prepared WT mouse brain lysate show no phosphorylation signal (Figure 11 input lanes).  Only 
after immunoprecipitation of the GABAB1 subunits a pS867 signal was obtained (Figure 11, GABAB1 
immunoprecipitation lanes). For negative control, an immunoprecipitation was done with adult 
GABAB1 knock out Balb/C mice (R1
-/-). 
For immunoprecipitation, the mouse brain lysate first had to be precleared with agarose G-
protein (Roche) 4°C. Immunoprecipitation is done with protein agarose G, coupled with the mouse 
polyclonal GABAB1 antibody (Abcam). 
Comparing the immunoprecipitation with the input lanes, a clear accumulation of both GABAB1 
subunit isoforms (Figure 11, lower GABAB1 blot) is obvious. This accumulation is specific, as suggested 
by the mouse immunoglobulin control (lanes IgM). The pS867 antibody clearly shows S867 
phosphorylation at the immunoprecpitated GABAB1 subunits. Moreover, the pS867 antibody unveils 
that S867 phosphorylation is predominantly at GABAB1b isoforms.  
CaMKII was shown to be concentrated at the postsynaptic terminal (Colbran, 2004). Various 
localization studies claim that the GABAB1b isoforms are postsynaptically located on dendritic spines 
at the glutamatergic synapses (Vigot, 2006, Ulrich, 2007, Guetg, 2009). It cannot be excluded that 
GABAB1a isoforms are also phosphorylated by CaMKII at S867, since GABAB1a isoforms, fewer than 
GABAB1b isoforms, are also found on postsynaptic terminal of glutamatergic synapses (Guetg, 2009). 
The native S867 phosphorylation was only visible after immunoprecipitation of the GABAB1 subunits. 
The S867 phosphorylation, that will be shown later, is part of a modulatory and reversible process. It 
is then anticipated that at any time-point, only a small population of native GABAB1 isoforms remains 
in its phosphorylated state. By immunoprecipitation the amount of phosphorylated GABAB1 subunits 
can be accumulated.   
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4.2.5.4 NMDA treatment of cortical cultures increases S867 phosphorylation 
CaMKII and glutamate receptors are integral parts of synaptic plasticity that underlie learning and 
memory. The simplest model for long-term potentiation postulates that CaMKII is activated by Ca2+ 
influx through NMDA (N-methyl-D-aspartate) receptors (Malenka, 1999). This calcium influx induced 
a potentiation of synaptic efficacy by inducing synaptic receptor insertions (Rongo, 1999, Hayashi, 
2000) and increased single-channel conductance of AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole 
propionic acid) receptors (Derkach, 1999).  Additionally, translocation of CaMKII to the synapse in 
hippocampal neurons was shown to be NMDA receptor-induced (Bayer, 2001). Consequently, it 
seemed essential in the course of the present study to analyze the effect of NMDA receptors on 
GABAB1 S867 phosphorylation. Therefore cultured cortical neurons from wild type Balb/C mouse 
embryos (DIV 14) were treated with NMDA. During the recovery time, S867 should then be 
phosphorylated if the activation of NMDA receptors stimulates the phosphorylation by CAMKII. 
Immunoprecipitation of GABAB1 subunits showed the following result; a recovery time of 7 minutes 
shows a S867 phosphorylation signal (Figure 12, second lane), whereas the untreated cell cultures 
show no weak basal phosphorylation of S867 (Figure 12, first lane). In the standard NMDA treatment 
protocol, although it has a longer reaction time of 30 minutes (3 minutes of NMDA application and 
27 minutes of recovery time after application), no pS867 phosphorylation signal could be observed in 
several experiments (not shown). This is not surprising, the decrease of the S867 phosphorylation 
signal after 30 minutes, compared to 10 minutes, is probably due to the advanced natural 
dephosphorylation processes, reducing the number of phosphorylated S867. NMDA receptor 
activation under increased neuronal activity augments phosphorylation of GABAB1 at S867. 
Figure 11. In vivo phosphorylation of 
the GABAB1b subunits isoforms. Brain 
lysate of wild type Balb/C mice (WT) 
shows no pS867 phosphorylation 
signal. After immunoprecipi-tation 
with a mouse GABAB1 antibody the 
pS867 antibody recognizes the 
phosphorylated GABAB1b subunit 
isoforms. The mouse brain lysate from 
GABAB1 knock out type Balb/C mice 
(R1-/-) serves as negative control. And 
the mouse immunoglobulin (IgM) 
control guarantees the specificity of 
the immunoprecipitation. 
 
Mouse brain lysate: 
 WT: wild type Balb/C mice  
R1-/-: GABAB1
-/- Balb/C mice 
Figure 12. NMDA receptor activation increases S867 phosphorlyation 
in cortical cell cultures. Cortical cell cultures (Div 14) were treated 
with NMDA. The loading amount was normalized using a GABAB1 
antibody (left panel).The first culture is NMDA untreated (untr.). The 
second culture was treated with NMDA and had a recovery time of 7 
minutes (NMDA).  
 
-GABAB1a 
Untr. NMDA Untr. NMDA 
GABAB1 pS867 
-GABAB1b 
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4.2.5.5 Preliminary immunohistochemical results with the pS867 antibody 
The pS867 antibody served a crucial role in the discovery of the phosphorylation site S867. It helped 
to unveil some of the S867 phosphorylating kinases in the in vitro approach. Additionally, the pS867 
antibody is essential for analyzing the distribution of the phosphorylated S867 in different brain 
regions. In the immunohistochemical experiments, coronal cryosections of mouse brains from WT 
mice and R1-/- mice were prepared as described in the paper of Kuramoto et al. (Kuramoto, 2007), 
and stained with the pS867 antibody. The secondary antibody was a donkey anti-rabbit/Cy2-
conjugated (Jackson Immunoresearch). The counterstaining was done with DAPI (4’,6-Diamidin-2’-
phenylindoldihydrochlorid). The sections were mounted with Fluorsafe (Calbiochem) and visualized 
with a Leica DMI6000 fluorescence microscope. The primary antibody was used in a dilution of 
1:100. Unfortunately, the pS867 antibody does not show specific staining for the pS867 in the 
GABAB1 subunit, since strong background staining in hippocampus and cortex was present in WT and 
as well R1-/- mice (Figure 13). To solve that problem, further conditions were tested. These conditions 
that could lead to an appropriate staining include increased CaMKII activity in combination with 
higher antibody dilutions or less stringent binding conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Immunohistochemistry on coronal cryosections with the pS867 antibody. Cryosections were 
made from wild type Balb/C mice (WT) and GABAB1 knock out Balb/C mice (R1
-/-). Left panels show 
hippocampal sections and right panels cortical sections. The top level shows the pS867 antibody staining.  
In the second level, the cell nuclei were marked by DAPI counterstaining. In the last lane both stainings are 
presented as a merge picture. No difference in pS867 staining could be observed between WT and R1-/- 
mice, showing unspecific binding of the p867 antibody in this experiment. 
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4.2.6 The phosphorylation of S867 is physiological relevant 
 
To examine if NMDA receptor mediated S867 phosphorylation regulates physiological functions of 
native GABAB receptors in neuronal cells, whole-cell patch clamp recordings were done from 
cultivated hippocampal neurons treated with NMDA. The GABAB receptor function at the neurons 
was monitored by recording of baclofen evoked current responses of G-protein coupled inwardly 
rectifying K+ channels. In the first set of experiments CaMKII activity in WT mouse neurons was 
blocked by perfusion of neurons with intracellular solution containing specific CaMKII inhibitor, KN-
93. In the second set hippocampal neurons isolated from R1-/- mouse were transfected with the non-
phosphorylable mutant from of GABAB1b: GABAB1b S867A. 
Dissociated hippocampal neurons (DIV 16-20) were perfused with a solution containing 145 
mM:NaCl, 2.5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 10 mM Hepes and 25 mM glucose , pH 7.3, 320 
mosm. GABAB receptors were activated by fast application of baclofen (100μM, for 5 seconds). The 
responses were recorded by patch-clamp recording from neurons dialyzed with intracellular solution 
(ICS) containing 102 mM K-gluconate, 32.5 mM KCl, 10 mM HEPES, 0.1 mM EGTA (0.1), 4 mM Mg-
ATP, 0.5 mM Tris-GTP and 10 mM Tris-phosphocreatine pH 7.2, 289 mosm. First, K+ currents evoked 
by baclofen were recorded from neurons voltage clamped at -50 mV before NMDA treatment. The 
stable response was achieved within 15 min of whole cell recording. Then the holding potential was 
decreased to -70 mV to prevent activation of voltage dependent Ca2+ conductance and NMDA 
(30μM) was applied for one minute together with the NMDA receptor co-activator glycine (10μM). 
Mg2+ was omitted from the NMDA containing extracellular solution to avoid the Mg2+ blocks of the 
NMDA receptors (middle graph in Figure 14 a-c) shows blocked NMDA receptor dependent 
glutamatergic currents). Thirty minutes after NMDA application, the baclofen responses was 
recorded at Vm = -50 mV. In the whole cell patch-clamp recordings of cultured WT mouse 
hippocampal neurons in absence of KN-93, a marked decline in baclofen-induced K+ current following 
NMDA application can be observed (Figure 14 a), upper part). Indeed, the amplitude decreases from 
84 pA to 19 pA following NMDA treatment. Treating the hippocampal neurons with KN-93, shows in 
the K+ current traces no drastic differences before and after the NMDA application; 69 pA and 36 pA 
before and after the treatment respectively (Figure 14 a), lower part). To quantify the effect of 
NMDA treatment on GABAB receptor function we have analyzed the maximal amplitudes of baclofen 
evoked responses before- and after NMDA treatment-. Our results showed that the amplitudes of 
after NMDA treatment responses were inhibited to 19.1 ± 14.4% (n = 5) of the responses obtained 
before before NMDA treatment (Figure 14. c), first bar graph, - KN-93). It indicates that NMDA 
receptor activation can effectively regulate the GABAB function. The inhibitory effect of NMDA 
receptors was at least partially mediated by CamKII activity as the inclusion of KN-93 into ICS relieved 
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NMDA-induced reduction of baclofen responses by nearly 50% (mean K+ amplitude after NMDA 
response was to 65.5 ± 20.2%, n = 5) (Figure 14.c), second bar graph).  
In the next series of experiments we testedthe hypothesis that mechanism underlying the 
NMDA induced inhibition of GABAB responses involves CaMKII-mediated phosphorylation of S867, in 
absence of KN-93. Neurons isolated from R1-/- mouse were transfected with WT GABAB1b (GB1b) or 
S867A substituted GABAB1b constructs (GB1bS867A) together with GABAB2. The GB1b construct has 
before NMDA treatment K+ amplitudes of 51 pA and after NMDA treatment amplitudes of 11 pA 
(Figure 14. b), upper part). Exchanging GB1b by the GB1bS867A construct shows that the before 
NMDA treatment amplitude was 57 pA before and 32 pA for the after NMDA treatment amplitude 
(Figure 14. b) lower part). The WT GABAB1b construct shows 80% (SD 11%) reduction of the K
+ 
response after NMDA application compared to the response before NMDA treatment before the 
NMDA application. The K+ current amplitude after NMDA treatment is around 11 pA roughly the 
same value as the NMDA treated WT mouse neurons. Although NMDA was applied, the S867A 
GABAB1b substitution rescues the K
+ response to around 64% (SD 16%) of the baclofen elicited K+ 
response before NMDA application. The measured K+ amplitude after NMDA is around 32 pA. 
The results obtained from the transfected R1-/- mouse neurons show a similar response to NMDA 
than the one observed with WT mouse neurons. Indeed, the K+ current amplitude decreases in the 
WT mouse neurons and WT GABAB1b construct transfected R1
-/- mouse neurons. Conversely, the 
decrease in the K+ response was almost prevented in WT mouse neurons in appearance of KN-93 and 
S867A GABAB1b construct transfected R1
-/- mouse neurons. 
 
Both set of experiments confirmed that NMDA receptor mediated activation of CaMKII 
phosphorylates the GABAB1b isoform subunit at S867, leading to a big decrease of GABAB receptor 
induced K+ response, probably trough the suggested internalization of the GABAB receptors trough 
NMDA receptor activation leads to a drastic increase in intracellular Ca2+ concentration triggering 
CaMKII activation. The CaMKII mediated phosphorylation of the GABAB1b subunit isoforms at S867 
leads to a strong decrease in postsynaptic inhibitory K+ current induced by baclofen. The measured 
decrease indicates a loss of the of the GABAB receptor response. An internalization of surface GABAB 
receptors could straightforwardly explain the observed reduction in the evoked K+ currents. 
Additionally, a phosphorylation mimetic S867D GABAB1b construct will be generated. The transfection 
of that construct should show a reduced K+ response after the NMDA treatment. Further 
explanations, on how the S867 phosphorylation could decrease GABAB receptors response, will be 
clarified in the following final discussion chapter. 
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Figure 14. In cultivated hippocampal neurons (DIV 16-20), NMDA reduces the inhibition of K+ channel 
activation induced by baclofen. A) Baclofen evoked K+ response after NMDA application (middle graph shows 
the blocking of NMDA receptor evoked glutamatergic currents: holding potential was set to -70 mV, NMDA 
(30μM) was applied for one minute together with the NMDA receptor co-activator glycine (10μM), to avoid 
the Mg2+ blocks of the NMDA receptors, no Mg2+ was in the NMDA containing extracellular solution). The 
whole cell patch-clamp recordings of cultured WT mouse hippocampal neurons in absence of KN-93 show a 
marked decline in baclofen-induced K+ current following NMDA application. Indeed, the amplitude decreases 
from 84 pA to 19 pA following NMDA treatment. The current traces from WT mouse hippocampal neurons 
pretreated with KN-93 show no strong variation before and after the NMDA application; 69 pA and 36 pA 
before and after the treatment respectively. B) Dissociated cultured hippocampal neurons from R1-/- mouse 
(DIV 16-20) cells were transfected in absence of KN-93 with a WT GABAB1b (GB1b) construct; before NMDA 
the K+ amplitude was 51 pA and 11 pA after the treatment. Changing the WT GB1b construct by the S867A 
GABAB1b (GB1bS867A) substitution construct shows that the amplitude was 57 pA before and 32 pA after 
NMDA treatment. C) The effect of NMDA treatment on GABAB receptor function has been quantified by 
normalizing the K+ amplitude after the treatment to the one before. In WT mouse neurons NMDA application 
in absence of KN-93 (first bar graph) results in a current of 19% (SD 14%). KN-93 application (second bar 
graph) rescues the measured K+ amplitude to 60% (SD 20%). In R1-/- mouse neurons transfected with a WT 
GB1b construct (third bar graph) the results show a reduction in the K+ response after the NMDA treatment to 
20% (SD 11%). The transfection of the GB1bS867A (fourth bar graph) inhibits the NMDA mediated decrease 
and shows K+ currents of 64% (SD 16%) of before NMDA treatment values. 
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V. Final discussion  
The identification of a CaMKII phosphorylation site on a major neuronal receptor is of a special 
significance. All brain functions need, for an optimal functioning, an adapted balance of excitation 
and inhibition. The GABAB receptor was the last major brain receptor in the CNS to be cloned 
(Kaupmann, 1997). The metabotropic GABAB receptor binds GABA, the main inhibitory 
neurotransmitter in the mammalian nervous system. For a long-time, it was generally assumed that 
the GABAB receptors system included several pharmacologically distinct receptor subtypes, like the 
related mGluR family. However, only two receptor subtypes were identified; GABAB(1a,2) and 
GABAB(1b,2) (Kaupmann, 1998a).  It is unclear how this small receptor heterogeneity ensures the 
differing electrophysiological and pharmacological in vivo responses observed for native GABAB 
receptors. As previously discussed, the differing subcellular localization of the two receptor subtypes 
is believed to be the reason for the differing behavior of both subtypes (Vigot, 2006, Guetg, 2009). 
The inhibitory effects of GABAB receptor activation on the brain are typical for a GPCR, slow and 
prolonged. The presynaptic activation of these receptors lead to the modulation of adenylate cyclase 
activity or to the blocking of voltage-dependent Ca2+ channels which inhibit neurotransmitters 
release.  On the other hand, postsynaptic receptors activation leads to a modulation in the gating of 
Kir3-type K+ channels. 
Surprisingly, GABAB receptor regulating mechanisms remain unidentified to a great extent. However, 
it is thought that receptor-associated proteins and direct posttranslational modifications influence 
the receptor function. Phosphorylation by protein kinases is known as one of the most important 
post-translational modifications (Hunter, 1995).  The importance of protein kinases in regulating 
cellular activities is already reflected by the large number of protein kinases related genes present in 
eukaryotic genomes; protein kinases are one of the largest superfamilies accounting for 1.7% of the 
human genome (Manning, 2002). Protein kinases were found to be enriched in the brain, where they 
play a critical role in the nervous systems such as memory formation and learning processes. Protein 
kinases also influence the GABAB receptors. For instance, PKA phosphorylates the GABAB receptor at 
the site S892 causing an elongation of the inhibitory action of GABAB receptors (Couve, 2002). This 
observation was first contradictory to the prevailing dogma being that phosphorylation reduces the 
GPCRs activity either by increasing receptor desensitization or by removing receptors from the cell 
surface. S892 phosphorylation by PKA strengthens the presence of GABAB receptors at cell surface, 
thereby enhancing the coupling of GABAB receptors to its effector. S783, another GABAB receptor 
phosphorylation site, was later described (Kuramoto, 2007). AMPK phosphorylates S783 thereby 
stabilizing the activating effects of the receptors on K+ currents; the K+ current rundown is finally 
reduced. AMPK phosphorylation at GABAB receptors is thought to be a novel neuroprotective 
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mechanism, which, under conditions of metabolic stress or ischemia, increases GABAB receptor 
function.  This consequently reduces excitotoxicity and promotes neuronal survival which diminishes 
the harms of a stroke incident. Both S892 and S783 sites are localized on the carboxyl-terminal of the 
GABAB2 subunit. For a long time, the GABAB2 subunit seemed to be the most interesting target for 
phosphorylation site search on the GABAB receptor; the GABAB2 subunit has the longer carboxyl-
terminal and the GABAB2 subunit is, due to the G-protein interaction, already localized near second 
messenger–dependent kinases. Indications for possible phosphorylation sites on the GABAB1 subunit 
existed, but were demonstrated only at the in vitro stage, e.g. the S917 was shown on GST-fusion 
protein containing the GABAB1 carboxyl-terminal, but not in vivo, and no physiological relevance 
could be attributed (Kuramoto, 2007). 
   
In my thesis I identified the first phosphorylation site localized on native GABAB1 subunits, serine 867 
(S867). S867 is juxtamembrane positioned on the GABAB1 carboxyl-terminal. It gets phosphorylated 
by CaMKII, mostly at the GABAB1b subunit isoform. CaMKII is implicated in a wide variety of neuronal 
functions, e.g. memory formation, receptor functioning, structural modification of the cytoskeleton, 
axonal transport, and gene expression (Hanson, 1992, Lisman, 1994, Yoshimura, 2000, Yoshimura, 
2002). GABAB receptor activity increases the phosphorylation of threonine 286 on α CaMKII (Xu, 
2008). Nevertheless, a CaMKII phosphorylation site on the GABAB receptor was never shown. The 
present findings finally confirm that CaMKII is regulating, via GABAB1-S867 phosphorylation, GABAB 
receptor response.  
 
CaMKII is highly abundant in neurons, especially enriched at synaptic endings (Kelly, 1984) and has a 
central role in the regulation of glutamatergic synapses. Its implication in glutamatergic transmission 
has emerged largely from the study of LTP, an activity dependent strengthening of synapses that is 
thought to underlie some forms of learning and memory. At many excitatory synapses, LTP is 
triggered by Ca2+ entry into the postsynaptic cell. Several lines of evidence indicate that CaMKII 
detects this Ca2+ elevation and initiates the biochemical cascade that potentiates synaptic 
transmission by recruiting AMPA and NMDA receptors to the postsynaptic membrane (Malenka, 
1989b, Malinow, 1989, Bayer, 2001, Lisman, 2002). CaMKII might not only induce LTP but might also 
be responsible for the persistence of LTP, therefore contributing to memory formation. The strongest 
evidence for this idea comes from the observation that CaMKII remains activated for at least one 
hour after LTP induction and autophosphorylation of threonine 286 is crucial for its persistent 
activation; a mutation that eliminates phosphorylation of this site blocks LTP (Lisman, 2002).  
 
The molecular mechanism underlying the phosphorylation of S867 by CaMKII points in the same 
direction as synaptic plasticity. Indeed, regulation of synaptic transmission depends on the 
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availability of surface neurotransmitter receptors and surface GABAB receptor levels were shown to 
be decreased in presence of glutamate. The alanine substitution of S867 (S867A) that prevents S867 
phosphorylation renders GABAB receptors refractory to NMDA-mediated internalization. KN-93 
application or the use of the S867A mutant abolished, in hippocampal dissociated neurons, the 
reduction of the GABAB receptor elicited K
+ currents after the NMDA treatment. Interestingly, the 
receptors ability to evoke inhibitory K+ response was preserved. This result also indicates that S867 
phosphorylation leads to an internalization of the GABAB receptors. The glutamate induced reduction 
of surface GABAB receptors was postulated to be mediated by a dynamin-dependent clathrin 
pathway (Vargas, 2008). To confirm that the NMDA mediated internalization works via the same 
pathway, the internalization should be abolished under hypertonic concentrations of sucrose 
(Grampp, 2007) or exposure to low K+ concentrations (Bayer, 2001) conditions inhibiting clathrin-
dependent internalizations. Clean and specific inhibition of the dynamin-dependent clathrin pathway 
in hippocampal cells was made possible by the use of dynasore. Dynasore has a potent in vitro 
inhibitory effect on the GTPase activity of dynamin1, dynamin2 and Drp1but not on other small 
GTPases (Macia, 2006). The effects of the dynasore administration can be studied using the 
immunofluorescence-based internalization assay. Additionally, cell surface ELISA and biotinylation 
assay, with cultured neuronal cells, should be also considered. Optionally, it can be argued that S867 
phosphorylation does not contribute to GABAB receptors internalization but only reduce their 
recycling to the membrane surface. However, this discrepancy can be solved by transfecting inactive 
Rab protein mutant in Rab protein deficient cells (Glodowski, 2007). Rab proteins are guanosine 
triphosphateases that mediate the recycling and trafficking of endocytosed vesicles to the cell 
surface. The inactive Rab mutant should not reduce the number of surface GABAB receptors if the 
phosphorylation is involved in receptor internalization rather than receptor recycling. 
The S867 phosphorylation was predominantly found at the native GABAB1b subunit which is, along 
with CaMKII, concentrated in the same postsynaptic compartments (Kennedy, 1983). The two GABAB 
receptor subtypes GABAB(1a,2) and GABAB1(b,2) produce different responses at axonal and dendritic 
effectors when pharmacologically activated by a saturating concentration of baclofen (Perez-Garci, 
2006, Shaban, 2006, Vigot, 2006, Ulrich, 2007). The diverse pharmacological reaction of the two 
subtypes was explained by the distinct distribution profile of the GABAB1a and GABAB1b subunits to 
axonal and dendritic compartments respectively (Vigot, 2006, Guetg, 2009). Their expressions are 
also under separate transcriptional control which influence the ratio of receptor subtypes in 
individual neurons (Steiger, 2004). S867 phosphorylation represents a selective and specific 
modification between the two subunits. Primary, the GABAB1b subunits are controlled by the S867 
phosphorylation effect. Transient high NMDA release leads to S867 GABAB1b subunit phosphorylation 
consequently reducing the inhibitory GABAB response in dendritic spines. This decrease in inhibition 
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contributes to an increased synaptic transmission efficacy. For this reason, one can anticipate a 
contribution of S867 phosphorylation to LTP and long-term depression (LTD) formation. LTD, the 
opposing process of LTP, requires also an NMDAR dependent rise in the postsynaptic Ca2+ 
concentration, which preferentially activates a protein-phosphatase cascade that includes calcineurin 
and phosphatase 1 (Carroll, 2001). The phosphatases could potentially dephosphorylate the pool of 
S867 phosphorylated GABAB receptors.  The internalization of the GABAB would then be reduced 
consequently leading to an increased inhibitory transmission in the CNS. One can then expect that 
the dephosphorylation of S867 could probably contribute to LTD like phenomenon; the inhibitory 
fence of the gabaergic system would be reset and even strengthened. 
 
Further effects on the GABAB receptor system through the S867 phosphorylation by CaMKII are 
imaginable. CaMKII phosphorylation was shown to regulate mGluR1 trafficking to different dendritic 
compartments (Kielland, 2009) and to influence the availability of Homer3 for its targets in the 
postsynaptic densities (Mizutani, 2008). Similarly, GABAB1 subunit phosphorylation could also 
potentially leads to a conformational change of the subunit which would increase the binding to 
scaffolding proteins such as β-arrestins, as shown for other GPCRs, e.g. anaphylatoxin receptor 
(Braun, 2003).  
The NMDA receptor mediated Ca2+ influx can activate, in addition to CaMKII, the kinase PKA 
(Moyano, 2004). Since PKA was shown in vitro to phosphorylate S867; further attention should be 
paid to a possible in vivo phosphorylation of S867 by PKA. This can be done by repeating the NMDA 
treatment experiments but in the presence of the cAMP–PKA pathway activator or inhibitor; e.g. 
forskolin or the PKA inhibitor peptide14-22 or Walsh peptide (Moreno-Delgado, 2009). PKA also 
mediates crucial physiological functions in the brain, especially in processes like LTP (Anwyl, 2009). 
GABAB receptors are known to influence PKA activity by decreasing cAMP production, via their 
restrictive action on adenylate cyclase. PKA phosphorylates large arrays of proteins involved in mood 
disorders; e.g. Rap-1 (a member of the Ras family and is highly expressed in the CNS) (Dwivedi, 2008). 
Additionally they are many significant intersections between GABAB receptors and PKA activity. 
Indeed, via PKA dependent pathways, presynaptic GABAB receptors decrease the release of GABA 
from autoreceptors.  This mechanism has an important role in the regulation of cholinergic 
transmission in the nucleus basalis of Meynert (Kubota, 2003), where a decrease in acetylcholine 
production is a key component in Alzheimer disease etiology (Freund, 2009). PKA and GABAB 
receptors are also essential in the sleep-wake behavior of mammals (Datta, 2007). Application of a 
PKA activator to Sprague-Dawley rats induces REM sleep, whereas baclofen application has the 
opposite effect (Datta, 2007).  
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Concluding, the phosphorylation site S867 can be seen as major part of a feedback mechanism. The 
active GABAB receptors decrease the activity of CaMKII and PKA. The physiological S867 
phosphorylation by CaMKII and potentially by PKA, antangonizes the decrease in the kinases activity. 
S867 phosphorylation reduces the inhibitory activity of GABAB receptors. This feedback mechanism 
would ensure a fine tunning of the inhibitory transmission in the CNS that could otherwise not be 
guaranteed. S867 is also part of the cross-talk between the glutamatergic and gabaergic nervous 
system. The NMDA-dependent phosphorylation of S867 by CaMKII internalizes the whole GABAB 
receptor. Consequently, the inhibitory response of the gabaergic system is locally decreased, 
whereas the excitatory circuit is enhanced; further recruitment of AMPA and NMDA receptor is then 
facilitated, phenomenon also observed during LTP. GABAB receptor subtype specificity of S867 
phosphorylation could be seen as an additional explanation for the different GABAB(1a,2) and 
GABAB(1b,2) receptors localization.  In conclusion, S867 phosphorylation plays an active part in the 
orchestration of synaptic plasticity and clearly manifests many possibilities for further scientific 
findings on the inhibitory effect of GABAB receptors on the CNS. Especialy the generation of a GABAB1 
S867A mice model could be an important landmark in the study of the role of S867 phosphorylation 
on the CNS. On such a mice model the regulatory effect of the S867 phosphorylation on the 
inhibitory gabaergic is able to get studied under different and the most physiological ways. The 
development of new research avenues on that subject enables the development of new innovative 
approches for the treatment of neurological and psychiatric diseases. 
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